The global nuclear medicine market is projected to reach USD 21.01 billion by 2030, growing from USD 10.41 billion in 2025 at a CAGR of 15.1% during the forecast period. This projection is driven by the growing demand for diagnostic and therapeutic radiopharmaceuticals and medical radioisotopes in the oncology, cardiology, and neurology fields. Additionally, the increased utilization of targeted radionuclide therapies, growth in cyclotron and reactor-based production of radioisotopes, and enhanced availability of these products through nuclear pharmacy networks are enhancing the growth of the market. Moreover, there is a significant increase in the use of radiopharmaceuticals across the globe as new ones are constantly developed and approved by regulatory bodies. This increased use of radiopharmaceuticals is further driving the growth of the market. ![Nuclear Medicine Market]( "Nuclear Medicine Market")
In-depth interviews were conducted with chief executive officers (CEOs), directors, and other executives from various key organizations operating in the authentication and brand protection marketplace.
The hospitals segment is projected to account for the largest share during the forecast period.
By end user, the hospitals segment is projected to account for the largest share of the nuclear medicine market during the forecast period. This projection is based on the capability of hospitals in preparing and administering radiopharmaceuticals through complex processes, available licensed facilities to deal with radioisotopes, and the presence of specialized nuclear medicine experts. Additionally, the presence of large volumes of patients, combined with diagnostic and therapeutic services, and well-established reimbursement systems in hospitals, is further expected to drive the growth of the segment in the coming years.The therapeutic applications segment is projected to register a higher growth than the diagnostic applications segment during the forecast period.
The therapeutic applications segment is projected to register a higher growth than the diagnostics applications segment during the forecast period. This projection is driven by the rising application of targeted radiopharmaceutical therapies and radioisotopes in treating cancer, especially in theranostics. Increasing clinical efficacy of radionuclide therapies and growing regulatory approval and investment in the production of therapeutic radioisotopes are boosting the acceptance across healthcare providers.Asia Pacific is projected to witness the highest growth rate during the forecast period.
Asia Pacific is projected to register the highest growth in the nuclear medicine market over the forecast period. This is due to the rising demand for radiopharmaceuticals and radioisotopes because of factors like increasing cancer prevalence, hospital facilities expansion, and growing access to nuclear medicine services. Additionally, the production of radioisotopes and the enhancement of regulatory infrastructure and supply chains by the governments are also increasing the growth of the markets in the region faster. Moreover, the growing healthcare spending and the rising awareness of early diagnosis and specific treatments are contributing to the rise in the number of nuclear medicine procedures.In-depth interviews were conducted with chief executive officers (CEOs), directors, and other executives from various key organizations operating in the authentication and brand protection marketplace.
The breakdown of primary participants is mentioned below:
- By Company Type - Tier 1 - 64%; Tier 2 - 23%; and Tier 3 - 13%
- By Designation - C Level - 35%; Director Level - 25%; and Others - 40%
- By Region - North America - 44%; Europe - 23%; Asia Pacific - 28%; Latin America - 3%; Middle East & Africa - 2%
Key Players in the Nuclear Medicine Market
The key players operating in the nuclear medicine market include GE HealthCare (US), Cardinal Health (US), Curium (France), Bayer AG (Germany), Lantheus Holdings, Inc. (US), Novartis AG (Switzerland), Jubilant Pharmova Limited (India), Bracco Imaging S.P.A (Italy), Pharmalogic Holdings Corp. (US), NTP Radioisotopes SOC Ltd. (South Africa), Nordion Inc. (Canada), Siemens Healthineers AG (Germany), NorthStar Medical Radiosiotopes, LLC (US), Eckert & Ziegler (Germany), Isotope JSC (Russia), Global Medical Solutions (US), Telix Pharmaceuticals Limited (Australia), PDRadiopharma Inc. (Japan), ITM Isotope Technologies Munich SE (Germany), BWX Technologies Inc. (US), SHINE Technologies, LLC (US), Isotopia (Israel), Institutes of Isotopes (Hungary), China Isotope & Radiation Corporation (China), and IRE Elit (Turkey).Research Coverage
The report analyzes the nuclear medicine market and aims to estimate the market size and future growth potential of various market segments by type, application, volume assessment, end user, and region. The report provides a competitive analysis of the key players operating in this market, along with their company profiles, product offerings, recent developments, and key market strategies.Reasons to Buy the Report
This report will enrich established firms as well as new entrants/smaller firms to gauge the pulse of the market, which, in turn, would help them garner a greater share of the market. Firms purchasing the report could use one or a combination of the following strategies to strengthen their positions in the market.This report provides insights into:
- Analysis of key drivers (Increasing incidence and prevalence of target conditions, development of alpha-radioimmunotherapy-based targeted cancer treatments, initiatives to reduce demand and supply gap of Mo-99), restraints (Short half-life of radiopharmaceuticals), opportunities (Use of radiopharmaceuticals in neurological applications, growth opportunities in emerging economies), challenges (Hospital budget cuts and high equipment costs) influencing the growth of the nuclear medicine market
- Product Development/Innovation: Detailed insights into upcoming technologies, research & development activities, and product launches in the nuclear medicine market
- Market Development: Comprehensive information on the lucrative emerging markets (based on type, application, volume assessment, and end user) across regions
- Market Diversification: Exhaustive information about the product portfolios, growing geographies, recent developments, and investments in the nuclear medicine market
- Competitive Assessment: In-depth assessment of market share, growth strategies, product offerings, and capabilities of the leading players [GE HealthCare (US), Cardinal Health (US), Curium (France), Bayer AG (Germany), and Lantheus Holdings, Inc. (US)] operating in the nuclear medicine market
Table of Contents
1 Introduction
1.1 Study Objectives
1.2 Market Definition
1.3 Study Scope
1.3.1 Market Segmentation & Regional Scope
1.3.2 Regional Scope
1.3.3 Inclusions & Exclusions
1.3.4 Years Considered
1.4 Currency Considered
1.5 Limitations
1.6 Stakeholders
1.7 Summary of Changes
1.2 Market Definition
1.3 Study Scope
1.3.1 Market Segmentation & Regional Scope
1.3.2 Regional Scope
1.3.3 Inclusions & Exclusions
1.3.4 Years Considered
1.4 Currency Considered
1.5 Limitations
1.6 Stakeholders
1.7 Summary of Changes
2 Executive Summary
2.1 Market Highlights & Key Insights
2.2 Key Market Participants: Mapping of Strategic Developments
2.3 Disruptive Trends in Nuclear Medicine Market
2.4 High-Growth Segments
2.5 Regional Snapshot: Market Size, Growth Rate, and Forecast
2.2 Key Market Participants: Mapping of Strategic Developments
2.3 Disruptive Trends in Nuclear Medicine Market
2.4 High-Growth Segments
2.5 Regional Snapshot: Market Size, Growth Rate, and Forecast
3 Premium Insights
3.1 Nuclear Medicine Market Overview
3.2 North America: Nuclear Medicine Market, by Type & Country
3.3 Nuclear Medicine Market: Geographic Snapshot
3.4 Nuclear Medicine Market: Developed vs. Emerging Economies
3.2 North America: Nuclear Medicine Market, by Type & Country
3.3 Nuclear Medicine Market: Geographic Snapshot
3.4 Nuclear Medicine Market: Developed vs. Emerging Economies
4 Market Overview
4.1 Introduction
4.2 Market Dynamics
4.2.1 Drivers
4.2.1.1 Increasing Incidence and Prevalence of Target Conditions
4.2.1.2 Rapid Expansion of Radioligand & Targeted Radionuclide Therapy
4.2.1.3 Strategic Entry of Large Pharma & Capital Inflows
4.2.1.4 Initiatives to Reduce Demand and Supply Gap of Mo-99
4.2.2 Restraints
4.2.2.1 Short Half-Life of Radiopharmaceuticals
4.2.2.2 Structural Isotope Supply Fragility
4.2.3 Opportunities
4.2.3.1 Development of Alpha-Radioimmunotherapy-based Targeted Cancer Treatments
4.2.3.2 Use of Radiopharmaceuticals in Neurological Applications
4.2.3.3 Growth Opportunities in Emerging Economies and Expanding Pet Infrastructure
4.2.4 Challenges
4.2.4.1 High Capital Intensity of Nuclear Medicine Infrastructure and Hospital Budget Cuts
4.2.4.2 Workforce Shortage in Nuclear Medicine
4.3 Unmet Needs & White Spaces
4.4 Interconnected Markets & Cross-Sector Opportunities
4.5 Strategic Moves by Tier-1/2/3 Players
4.2 Market Dynamics
4.2.1 Drivers
4.2.1.1 Increasing Incidence and Prevalence of Target Conditions
4.2.1.2 Rapid Expansion of Radioligand & Targeted Radionuclide Therapy
4.2.1.3 Strategic Entry of Large Pharma & Capital Inflows
4.2.1.4 Initiatives to Reduce Demand and Supply Gap of Mo-99
4.2.2 Restraints
4.2.2.1 Short Half-Life of Radiopharmaceuticals
4.2.2.2 Structural Isotope Supply Fragility
4.2.3 Opportunities
4.2.3.1 Development of Alpha-Radioimmunotherapy-based Targeted Cancer Treatments
4.2.3.2 Use of Radiopharmaceuticals in Neurological Applications
4.2.3.3 Growth Opportunities in Emerging Economies and Expanding Pet Infrastructure
4.2.4 Challenges
4.2.4.1 High Capital Intensity of Nuclear Medicine Infrastructure and Hospital Budget Cuts
4.2.4.2 Workforce Shortage in Nuclear Medicine
4.3 Unmet Needs & White Spaces
4.4 Interconnected Markets & Cross-Sector Opportunities
4.5 Strategic Moves by Tier-1/2/3 Players
5 Industry Trends
5.1 Porter's Five Forces Analysis
5.1.1 Intensity of Competitive Rivalry
5.1.2 Bargaining Power of Suppliers
5.1.3 Bargaining Power of Buyers
5.1.4 Threat of Substitutes
5.1.5 Threat of New Entrants
5.2 Macroeconomic Indicators
5.2.1 Introduction
5.2.2 GDP Trends & Forecast
5.2.3 Trends in Global Healthcare Industry
5.2.4 Trends in Global Pharmaceutical Industry
5.3 Value Chain Analysis
5.4 Ecosystem Analysis
5.5 Pricing Analysis
5.5.1 Indicative Price of Nuclear Medicine Products, by Type, 2024
5.5.2 Indicative Price of Nuclear Medicine Products, by Region, 2024
5.6 Trade Analysis
5.6.1 Import Scenario for HS Code 2844
5.6.2 Export Scenario for HS Code 2844
5.6.3 Import Scenario for HS Code 3002
5.6.4 Export Scenario for HS Code 3002
5.7 Key Conferences & Events, 2026-2027
5.8 Trends/Disruptions Impacting Customers’ Businesses
5.9 Investment & Funding Scenario
5.10 Case Study Analysis
5.11 Impact of 2025 US Tariffs on Nuclear Medicine Market
5.11.1 Introduction
5.11.2 Key Tariff Rates
5.11.3 Price Impact Analysis
5.11.4 Impact on Country/Region
5.11.4.1 US
5.11.4.2 Europe
5.11.4.3 Asia-Pacific
5.11.5 Impact on End-use Industries
5.11.5.1 Hospitals
5.11.5.2 Diagnostic & Imaging Centers
5.11.5.3 Research & Academic Institutes
5.1.1 Intensity of Competitive Rivalry
5.1.2 Bargaining Power of Suppliers
5.1.3 Bargaining Power of Buyers
5.1.4 Threat of Substitutes
5.1.5 Threat of New Entrants
5.2 Macroeconomic Indicators
5.2.1 Introduction
5.2.2 GDP Trends & Forecast
5.2.3 Trends in Global Healthcare Industry
5.2.4 Trends in Global Pharmaceutical Industry
5.3 Value Chain Analysis
5.4 Ecosystem Analysis
5.5 Pricing Analysis
5.5.1 Indicative Price of Nuclear Medicine Products, by Type, 2024
5.5.2 Indicative Price of Nuclear Medicine Products, by Region, 2024
5.6 Trade Analysis
5.6.1 Import Scenario for HS Code 2844
5.6.2 Export Scenario for HS Code 2844
5.6.3 Import Scenario for HS Code 3002
5.6.4 Export Scenario for HS Code 3002
5.7 Key Conferences & Events, 2026-2027
5.8 Trends/Disruptions Impacting Customers’ Businesses
5.9 Investment & Funding Scenario
5.10 Case Study Analysis
5.11 Impact of 2025 US Tariffs on Nuclear Medicine Market
5.11.1 Introduction
5.11.2 Key Tariff Rates
5.11.3 Price Impact Analysis
5.11.4 Impact on Country/Region
5.11.4.1 US
5.11.4.2 Europe
5.11.4.3 Asia-Pacific
5.11.5 Impact on End-use Industries
5.11.5.1 Hospitals
5.11.5.2 Diagnostic & Imaging Centers
5.11.5.3 Research & Academic Institutes
6 Strategic Disruptions Through Technology, Patents, and Digital & AI Adoption
6.1 Key Emerging Technologies
6.1.1 Next-Generation Radioligand Therapy & Theranostics
6.1.2 Radioisotope Production Technologies
6.1.3 High-Specific-Activity Radiolabeling and Chelation Chemistry
6.1.4 Gmp Hot-Cell Manufacturing & Radiopharmaceutical Quality Control
6.1.5 Cold Kit & Generator Technologies
6.1.6 Decentralized Isotope Production & Advanced Radiopharmacy Systems
6.2 Complementary Technologies
6.2.1 Automated Radiotracer Synthesis & Dispensing Systems
6.2.2 Dosimetry & Treatment Planning Technologies
6.3 Adjacent Technologies
6.3.1 Target Discovery & Radioligand Design Platforms
6.3.2 Integrated Theranostic Workflows & Data Platforms
6.3.3 AI-Enabled Quantitative Imaging & Workflow Automation
6.4 Technology/Product Roadmap
6.5 Patent Analysis
6.5.1 Patent Publication Trends for Nuclear Medicine Market
6.5.2 Insights: Jurisdiction & Top Applicant Analysis
6.6 Future Applications
6.6.1 Precision Oncology & Theranostics Expansion
6.6.2 Personalized Radionuclide Therapy Using Dosimetry-Guided Dosing
6.6.3 Early Disease Detection & Risk Stratification
6.6.4 Neurodegenerative & Neuroinflammatory Disorders
6.6.5 Inflammation, Infection, and Immune System Imaging
6.7 Impact of AI/Gen AI on Nuclear Medicine Market
6.7.1 Introduction
6.7.2 Market Potential of AI/Gen AI in Nuclear Medicine Market
6.7.3 Case Studies Related to AI/Gen AI Implementation
6.7.3.1 Clinical Validation of AI-Enabled Standardization and Workflow Efficiency in Psma Pet Imaging for Prostate Cancer
6.7.4 Impact of AI/Gen AI on Interconnected & Adjacent Ecosystems
6.7.4.1 Radiopharmacy, Manufacturing, and Quality Operations
6.7.4.2 Clinical Imaging, Dosimetry, and Treatment Planning Infrastructure
6.7.4.3 Hospital Systems, Regulatory Compliance, and Theranostic Data Platforms
6.7.5 User Readiness and Impact Assessment
6.7.5.1 User Readiness
6.7.5.1.1 User A: Hospitals
6.7.5.1.2 User B: Diagnostic & Imaging Centers
6.7.5.2 Impact Assessment
6.7.5.2.1 User A: Hospitals
6.7.5.2.1.1 Implementation
6.7.5.2.1.2 Impact
6.7.5.2.2 User B: Diagnostic & Imaging Centers
6.7.5.2.2.1 Implementation
6.7.5.2.2.2 Impact
6.1.1 Next-Generation Radioligand Therapy & Theranostics
6.1.2 Radioisotope Production Technologies
6.1.3 High-Specific-Activity Radiolabeling and Chelation Chemistry
6.1.4 Gmp Hot-Cell Manufacturing & Radiopharmaceutical Quality Control
6.1.5 Cold Kit & Generator Technologies
6.1.6 Decentralized Isotope Production & Advanced Radiopharmacy Systems
6.2 Complementary Technologies
6.2.1 Automated Radiotracer Synthesis & Dispensing Systems
6.2.2 Dosimetry & Treatment Planning Technologies
6.3 Adjacent Technologies
6.3.1 Target Discovery & Radioligand Design Platforms
6.3.2 Integrated Theranostic Workflows & Data Platforms
6.3.3 AI-Enabled Quantitative Imaging & Workflow Automation
6.4 Technology/Product Roadmap
6.5 Patent Analysis
6.5.1 Patent Publication Trends for Nuclear Medicine Market
6.5.2 Insights: Jurisdiction & Top Applicant Analysis
6.6 Future Applications
6.6.1 Precision Oncology & Theranostics Expansion
6.6.2 Personalized Radionuclide Therapy Using Dosimetry-Guided Dosing
6.6.3 Early Disease Detection & Risk Stratification
6.6.4 Neurodegenerative & Neuroinflammatory Disorders
6.6.5 Inflammation, Infection, and Immune System Imaging
6.7 Impact of AI/Gen AI on Nuclear Medicine Market
6.7.1 Introduction
6.7.2 Market Potential of AI/Gen AI in Nuclear Medicine Market
6.7.3 Case Studies Related to AI/Gen AI Implementation
6.7.3.1 Clinical Validation of AI-Enabled Standardization and Workflow Efficiency in Psma Pet Imaging for Prostate Cancer
6.7.4 Impact of AI/Gen AI on Interconnected & Adjacent Ecosystems
6.7.4.1 Radiopharmacy, Manufacturing, and Quality Operations
6.7.4.2 Clinical Imaging, Dosimetry, and Treatment Planning Infrastructure
6.7.4.3 Hospital Systems, Regulatory Compliance, and Theranostic Data Platforms
6.7.5 User Readiness and Impact Assessment
6.7.5.1 User Readiness
6.7.5.1.1 User A: Hospitals
6.7.5.1.2 User B: Diagnostic & Imaging Centers
6.7.5.2 Impact Assessment
6.7.5.2.1 User A: Hospitals
6.7.5.2.1.1 Implementation
6.7.5.2.1.2 Impact
6.7.5.2.2 User B: Diagnostic & Imaging Centers
6.7.5.2.2.1 Implementation
6.7.5.2.2.2 Impact
7 Regulatory Landscape
7.1 Regional Regulations & Compliance
7.1.1 Regulatory Bodies, Government Agencies, and Other Organizations
7.1.2 Regulatory Framework
7.1.2.1 North America
7.1.2.2 Europe
7.1.2.3 Asia-Pacific
7.1.2.4 Latin America
7.1.2.5 Middle East & Africa
7.1.3 Industry Standards
7.1.1 Regulatory Bodies, Government Agencies, and Other Organizations
7.1.2 Regulatory Framework
7.1.2.1 North America
7.1.2.2 Europe
7.1.2.3 Asia-Pacific
7.1.2.4 Latin America
7.1.2.5 Middle East & Africa
7.1.3 Industry Standards
8 Customer Landscape & Buyer Behavior
8.1 Introduction
8.2 Decision-Making Process
8.3 Buyer Stakeholders & Buying Evaluation Criteria
8.3.1 Key Stakeholders in Buying Process
8.3.2 Buying Criteria
8.4 Adoption Barriers & Internal Challenges
8.5 Unmet Needs from Various End-use Industries
8.5.1 Unmet Needs
8.5.2 End-user Expectations
8.6 Market Profitability
8.2 Decision-Making Process
8.3 Buyer Stakeholders & Buying Evaluation Criteria
8.3.1 Key Stakeholders in Buying Process
8.3.2 Buying Criteria
8.4 Adoption Barriers & Internal Challenges
8.5 Unmet Needs from Various End-use Industries
8.5.1 Unmet Needs
8.5.2 End-user Expectations
8.6 Market Profitability
9 Nuclear Medicine Market, by Type
9.1 Introduction
9.2 Diagnostic Nuclear Medicine
9.2.1 Spect Radiopharmaceuticals
9.2.1.1 Tc-99M
9.2.1.1.1 Dominant Role of Tc-99M in Spect to Boost Market Growth
9.2.1.2 I-123
9.2.1.2.1 Reduced Exposure to Radiation and Lower Risk of Patients Developing Radiation-Induced Cancer to Drive Demand
9.2.1.3 Tl-201
9.2.1.3.1 Most Commonly Used Substitute for Tc-99M in Cardiac Stress Tests to Support Market Growth
9.2.1.4 Ga-67
9.2.1.4.1 Long Half-Life of Ga-67 to Facilitate Easy Sales and Distribution
9.2.1.5 Other Spect Radiopharmaceuticals
9.2.2 Pet Radiopharmaceuticals
9.2.2.1 F-18
9.2.2.1.1 Advantages Such as Highly Accurate, Metabolism-based Cancer Imaging to Boost Demand
9.2.2.2 Rb-82
9.2.2.2.1 High Accuracy Offered by Rb-82 Isotopes to Support Market Growth
9.2.2.3 Other Pet Radiopharmaceuticals
9.3 Therapeutic Nuclear Medicine
9.3.1 Alpha Emitters
9.3.1.1 Ra-223
9.3.1.1.1 Rising Metastatic Prostate Cancer Burden and Demand for Bone-Targeted, Outpatient Alpha Therapy to Drive Adoption
9.3.2 Beta Emitters
9.3.2.1 I-131
9.3.2.1.1 I-131 to Account for Largest Share of Beta Emitters Market During Forecast Period
9.3.2.2 Y-90
9.3.2.2.1 Rising Incidence of Liver Cancers and Hepatocellular Carcinoma to Propel Growth
9.3.2.3 Sm-153
9.3.2.3.1 Increasing Incidence of Bone Metastasis to Drive Market
9.3.2.4 Lu-177
9.3.2.4.1 Rising Cancer Burden and Expanding Prrt Adoption to Fuel Growth
9.3.2.5 Other Beta Emitters
9.3.3 Brachytherapy Isotopes
9.3.3.1 I-125
9.3.3.1.1 I-125 to Account for Largest Share of Brachytherapy Isotopes Market
9.3.3.2 Ir-192
9.3.3.2.1 Precise, High-Dose Brachytherapy Across Multiple Cancers to Propel Market
9.3.3.3 Pd-103
9.3.3.3.1 Ability to Make Brachytherapy Permanent Implant Seeds for Early-Stage Prostate Cancer to Drive Adoption
9.3.3.4 Cs-131
9.3.3.4.1 Growing Use of Cs-131 in Gynecological Applications to Aid Growth
9.3.3.5 Other Brachytherapy Isotopes
9.2 Diagnostic Nuclear Medicine
9.2.1 Spect Radiopharmaceuticals
9.2.1.1 Tc-99M
9.2.1.1.1 Dominant Role of Tc-99M in Spect to Boost Market Growth
9.2.1.2 I-123
9.2.1.2.1 Reduced Exposure to Radiation and Lower Risk of Patients Developing Radiation-Induced Cancer to Drive Demand
9.2.1.3 Tl-201
9.2.1.3.1 Most Commonly Used Substitute for Tc-99M in Cardiac Stress Tests to Support Market Growth
9.2.1.4 Ga-67
9.2.1.4.1 Long Half-Life of Ga-67 to Facilitate Easy Sales and Distribution
9.2.1.5 Other Spect Radiopharmaceuticals
9.2.2 Pet Radiopharmaceuticals
9.2.2.1 F-18
9.2.2.1.1 Advantages Such as Highly Accurate, Metabolism-based Cancer Imaging to Boost Demand
9.2.2.2 Rb-82
9.2.2.2.1 High Accuracy Offered by Rb-82 Isotopes to Support Market Growth
9.2.2.3 Other Pet Radiopharmaceuticals
9.3 Therapeutic Nuclear Medicine
9.3.1 Alpha Emitters
9.3.1.1 Ra-223
9.3.1.1.1 Rising Metastatic Prostate Cancer Burden and Demand for Bone-Targeted, Outpatient Alpha Therapy to Drive Adoption
9.3.2 Beta Emitters
9.3.2.1 I-131
9.3.2.1.1 I-131 to Account for Largest Share of Beta Emitters Market During Forecast Period
9.3.2.2 Y-90
9.3.2.2.1 Rising Incidence of Liver Cancers and Hepatocellular Carcinoma to Propel Growth
9.3.2.3 Sm-153
9.3.2.3.1 Increasing Incidence of Bone Metastasis to Drive Market
9.3.2.4 Lu-177
9.3.2.4.1 Rising Cancer Burden and Expanding Prrt Adoption to Fuel Growth
9.3.2.5 Other Beta Emitters
9.3.3 Brachytherapy Isotopes
9.3.3.1 I-125
9.3.3.1.1 I-125 to Account for Largest Share of Brachytherapy Isotopes Market
9.3.3.2 Ir-192
9.3.3.2.1 Precise, High-Dose Brachytherapy Across Multiple Cancers to Propel Market
9.3.3.3 Pd-103
9.3.3.3.1 Ability to Make Brachytherapy Permanent Implant Seeds for Early-Stage Prostate Cancer to Drive Adoption
9.3.3.4 Cs-131
9.3.3.4.1 Growing Use of Cs-131 in Gynecological Applications to Aid Growth
9.3.3.5 Other Brachytherapy Isotopes
10 Nuclear Medicine Market, by Application
10.1 Introduction
10.2 Diagnostic Applications
10.2.1 Spect Applications
10.2.1.1 Cardiology
10.2.1.1.1 Rising Global Cardiovascular Disease Burden and Expanding, Evidence-Backed Cardiology Applications to Drive Growth
10.2.1.2 Bone Scans
10.2.1.2.1 High Precision of Spect to Boost Adoption of Bone Scans
10.2.1.3 Thyroid
10.2.1.3.1 Rising Demand for Combination Spect/CT Therapy to Drive Market Growth
10.2.1.4 Pulmonary Scans
10.2.1.4.1 High Accuracy and Sensitivity of Spect/CT Pulmonary Imaging to Boost Market
10.2.1.5 Other Spect Applications
10.2.2 Pet Applications
10.2.2.1 Oncology
10.2.2.1.1 Increasing Incidence of Cancer to Fuel Market Growth
10.2.2.2 Cardiology
10.2.2.2.1 Growing Preference for Fdg in Cardiac Imaging to Propel Market
10.2.2.3 Neurology
10.2.2.3.1 Increasing Incidence of Ad, Epilepsy, and Parkinson's Disease to Increase Adoption of Pet Imaging
10.2.2.4 Other Pet Applications
10.3 Therapeutic Applications
10.3.1 Thyroid Indications
10.3.1.1 Increasing Prevalence of Thyroid Disorders to Boost Market
10.3.2 Bone Metastasis
10.3.2.1 Introduction of Novel Therapies for Bone Metastasis to Positively Impact Market Growth
10.3.3 Endocrine Tumors
10.3.3.1 US to Dominate Therapeutic Nuclear Medicine Market for Endocrine Tumor Applications
10.3.4 Lymphoma
10.3.4.1 Development of New Isotopes for Treatment of Lymphoma to Present Huge Growth Opportunities
10.3.5 Other Therapeutic Applications
10.2 Diagnostic Applications
10.2.1 Spect Applications
10.2.1.1 Cardiology
10.2.1.1.1 Rising Global Cardiovascular Disease Burden and Expanding, Evidence-Backed Cardiology Applications to Drive Growth
10.2.1.2 Bone Scans
10.2.1.2.1 High Precision of Spect to Boost Adoption of Bone Scans
10.2.1.3 Thyroid
10.2.1.3.1 Rising Demand for Combination Spect/CT Therapy to Drive Market Growth
10.2.1.4 Pulmonary Scans
10.2.1.4.1 High Accuracy and Sensitivity of Spect/CT Pulmonary Imaging to Boost Market
10.2.1.5 Other Spect Applications
10.2.2 Pet Applications
10.2.2.1 Oncology
10.2.2.1.1 Increasing Incidence of Cancer to Fuel Market Growth
10.2.2.2 Cardiology
10.2.2.2.1 Growing Preference for Fdg in Cardiac Imaging to Propel Market
10.2.2.3 Neurology
10.2.2.3.1 Increasing Incidence of Ad, Epilepsy, and Parkinson's Disease to Increase Adoption of Pet Imaging
10.2.2.4 Other Pet Applications
10.3 Therapeutic Applications
10.3.1 Thyroid Indications
10.3.1.1 Increasing Prevalence of Thyroid Disorders to Boost Market
10.3.2 Bone Metastasis
10.3.2.1 Introduction of Novel Therapies for Bone Metastasis to Positively Impact Market Growth
10.3.3 Endocrine Tumors
10.3.3.1 US to Dominate Therapeutic Nuclear Medicine Market for Endocrine Tumor Applications
10.3.4 Lymphoma
10.3.4.1 Development of New Isotopes for Treatment of Lymphoma to Present Huge Growth Opportunities
10.3.5 Other Therapeutic Applications
11 Nuclear Medicine Market: Procedural Volume Assessment
11.1 Introduction
11.2 Diagnostic Procedures
11.2.1 High Prevalence of Cancer and Cardiac Diseases to Drive Market Growth
11.3 Therapeutic Procedures
11.3.1 Growing Demand for Non-Invasive Methods to Support Market Growth
11.2 Diagnostic Procedures
11.2.1 High Prevalence of Cancer and Cardiac Diseases to Drive Market Growth
11.3 Therapeutic Procedures
11.3.1 Growing Demand for Non-Invasive Methods to Support Market Growth
12 Nuclear Medicine Market, by End-user
12.1 Introduction
12.2 Hospitals
12.2.1 Growing Volume of Diagnostic Procedures to Drive Market Growth
12.3 Diagnostic & Imaging Centers
12.3.1 Growing Number of Private Imaging Centers to Support Market Growth
12.4 Academic & Research Institutes
12.4.1 Increasing Collaborations Between Nuclear Imaging Companies and Academia to Propel Market Growth
12.5 Other End-users
12.2 Hospitals
12.2.1 Growing Volume of Diagnostic Procedures to Drive Market Growth
12.3 Diagnostic & Imaging Centers
12.3.1 Growing Number of Private Imaging Centers to Support Market Growth
12.4 Academic & Research Institutes
12.4.1 Increasing Collaborations Between Nuclear Imaging Companies and Academia to Propel Market Growth
12.5 Other End-users
13 Nuclear Medicine Market, by Region
13.1 Introduction
13.2 North America
13.2.1 Macroeconomic Outlook for North America
13.2.2 US
13.2.2.1 US to Dominate North American Nuclear Medicine Market During Forecast Period
13.2.3 Canada
13.2.3.1 Increasing Initiatives for Medical Isotope Development to Support Market Growth
13.3 Europe
13.3.1 Macroeconomic Outlook for Europe
13.3.2 Germany
13.3.2.1 Well-Established Healthcare System to Drive Market Growth
13.3.3 France
13.3.3.1 Rising Incidence of Diseases Such as Cancer, Alzheimer's, and Parkinson's Disease to Favor Market Growth
13.3.4 UK
13.3.4.1 Growing Demand for Diagnostic Imaging and Growing Awareness to Drive Market Growth
13.3.5 Italy
13.3.5.1 Aging Demographics, High Procedure Volumes, Increasing Cancer Incidence, and Domestic Isotope Self-Sufficiency to Fuel Growth
13.3.6 Spain
13.3.6.1 Rising Disease Prevalence, Regulatory Modernization, and Targeted Radioligand Expansion to Create Supportive Environment
13.3.7 Rest of Europe
13.4 Asia-Pacific
13.4.1 Macroeconomic Outlook for Asia-Pacific
13.4.2 Japan
13.4.2.1 Japan to Dominate APAC Nuclear Medicine Market
13.4.3 China
13.4.3.1 Increasing Nuclear Medicine Infrastructure and Growing Prevalence of Chronic Diseases to Augment Market
13.4.4 India
13.4.4.1 Rising Cancer and Cardiovascular Disease Burden and Rapid Expansion of Nuclear Medicine Infrastructure to Boost Market
13.4.5 South Korea
13.4.5.1 Accelerating Pet Utilization and Maturing Domestic Rpt Innovation Ecosystem to Augment Market
13.4.6 Australia
13.4.6.1 Rising Cancer Prevalence, High Pet Penetration, and Growing Domestic Isotope Production to Support Growth
13.4.7 Rest of Asia-Pacific
13.5 Latin America
13.5.1 Macroeconomic Outlook for Latin America
13.5.2 Brazil
13.5.2.1 Rising Cancer Incidence and Expanding Imaging Infrastructure to Drive Market
13.5.3 Mexico
13.5.3.1 Rising Cancer and Cardiovascular Disease Burden and Expanding Private-Sector Pet Access to Drive Market
13.5.4 Rest of Latin America
13.6 Middle East & Africa
13.6.1 Macroeconomic Outlook for Middle East & Africa
13.6.2 GCC Countries
13.6.2.1 Growing Healthcare Needs and Favorable Government Support to Boost Market
13.6.3 Rest of Middle East & Africa
13.2 North America
13.2.1 Macroeconomic Outlook for North America
13.2.2 US
13.2.2.1 US to Dominate North American Nuclear Medicine Market During Forecast Period
13.2.3 Canada
13.2.3.1 Increasing Initiatives for Medical Isotope Development to Support Market Growth
13.3 Europe
13.3.1 Macroeconomic Outlook for Europe
13.3.2 Germany
13.3.2.1 Well-Established Healthcare System to Drive Market Growth
13.3.3 France
13.3.3.1 Rising Incidence of Diseases Such as Cancer, Alzheimer's, and Parkinson's Disease to Favor Market Growth
13.3.4 UK
13.3.4.1 Growing Demand for Diagnostic Imaging and Growing Awareness to Drive Market Growth
13.3.5 Italy
13.3.5.1 Aging Demographics, High Procedure Volumes, Increasing Cancer Incidence, and Domestic Isotope Self-Sufficiency to Fuel Growth
13.3.6 Spain
13.3.6.1 Rising Disease Prevalence, Regulatory Modernization, and Targeted Radioligand Expansion to Create Supportive Environment
13.3.7 Rest of Europe
13.4 Asia-Pacific
13.4.1 Macroeconomic Outlook for Asia-Pacific
13.4.2 Japan
13.4.2.1 Japan to Dominate APAC Nuclear Medicine Market
13.4.3 China
13.4.3.1 Increasing Nuclear Medicine Infrastructure and Growing Prevalence of Chronic Diseases to Augment Market
13.4.4 India
13.4.4.1 Rising Cancer and Cardiovascular Disease Burden and Rapid Expansion of Nuclear Medicine Infrastructure to Boost Market
13.4.5 South Korea
13.4.5.1 Accelerating Pet Utilization and Maturing Domestic Rpt Innovation Ecosystem to Augment Market
13.4.6 Australia
13.4.6.1 Rising Cancer Prevalence, High Pet Penetration, and Growing Domestic Isotope Production to Support Growth
13.4.7 Rest of Asia-Pacific
13.5 Latin America
13.5.1 Macroeconomic Outlook for Latin America
13.5.2 Brazil
13.5.2.1 Rising Cancer Incidence and Expanding Imaging Infrastructure to Drive Market
13.5.3 Mexico
13.5.3.1 Rising Cancer and Cardiovascular Disease Burden and Expanding Private-Sector Pet Access to Drive Market
13.5.4 Rest of Latin America
13.6 Middle East & Africa
13.6.1 Macroeconomic Outlook for Middle East & Africa
13.6.2 GCC Countries
13.6.2.1 Growing Healthcare Needs and Favorable Government Support to Boost Market
13.6.3 Rest of Middle East & Africa
14 Competitive Landscape
14.1 Overview
14.2 Key Player Strategies/Right to Win
14.2.1 Overview of Strategies Adopted by Key Players in Nuclear Medicine Market
14.3 Revenue Analysis, 2020-2024
14.4 Market Share Analysis, 2024
14.5 Brand/Product Comparison
14.6 Company Valuation & Financial Metrics
14.6.1 Financial Metrics
14.6.2 Company Valuation
14.7 Company Evaluation Matrix: Key Players, 2024
14.7.1 Stars
14.7.2 Emerging Leaders
14.7.3 Pervasive Players
14.7.4 Participants
14.7.5 Company Footprint: Key Players, 2024
14.7.5.1 Company Footprint
14.7.5.2 Region Footprint
14.7.5.3 Type Footprint
14.7.5.4 Application Footprint
14.8 Company Evaluation Matrix: Startups/SMEs, 2024
14.8.1 Progressive Companies
14.8.2 Responsive Companies
14.8.3 Dynamic Companies
14.8.4 Starting Blocks
14.8.5 Competitive Benchmarking: Startups/SMEs, 2024
14.8.5.1 Detailed List of Key Startups/SMEs
14.8.5.2 Competitive Benchmarking of Startups/SMEs
14.9 Competitive Scenario
14.9.1 Product Approvals
14.9.2 Deals
14.9.3 Expansions
14.9.4 Other Developments
14.2 Key Player Strategies/Right to Win
14.2.1 Overview of Strategies Adopted by Key Players in Nuclear Medicine Market
14.3 Revenue Analysis, 2020-2024
14.4 Market Share Analysis, 2024
14.5 Brand/Product Comparison
14.6 Company Valuation & Financial Metrics
14.6.1 Financial Metrics
14.6.2 Company Valuation
14.7 Company Evaluation Matrix: Key Players, 2024
14.7.1 Stars
14.7.2 Emerging Leaders
14.7.3 Pervasive Players
14.7.4 Participants
14.7.5 Company Footprint: Key Players, 2024
14.7.5.1 Company Footprint
14.7.5.2 Region Footprint
14.7.5.3 Type Footprint
14.7.5.4 Application Footprint
14.8 Company Evaluation Matrix: Startups/SMEs, 2024
14.8.1 Progressive Companies
14.8.2 Responsive Companies
14.8.3 Dynamic Companies
14.8.4 Starting Blocks
14.8.5 Competitive Benchmarking: Startups/SMEs, 2024
14.8.5.1 Detailed List of Key Startups/SMEs
14.8.5.2 Competitive Benchmarking of Startups/SMEs
14.9 Competitive Scenario
14.9.1 Product Approvals
14.9.2 Deals
14.9.3 Expansions
14.9.4 Other Developments
15 Company Profiles
15.1 Key Players
15.1.1 Novartis AG
15.1.1.1 Business Overview
15.1.1.2 Products Offered
15.1.1.3 Recent Developments
15.1.1.3.1 Product Approvals
15.1.1.3.2 Deals
15.1.1.3.3 Expansions
15.1.1.4 Analyst's View
15.1.1.4.1 Right to Win
15.1.1.4.2 Strategic Choices
15.1.1.4.3 Weaknesses & Competitive Threats
15.1.2 Lantheus Holdings, Inc.
15.1.2.1 Business Overview
15.1.2.2 Products Offered
15.1.2.3 Recent Developments
15.1.2.3.1 Deals
15.1.2.4 Analyst's View
15.1.2.4.1 Right to Win
15.1.2.4.2 Strategic Choices
15.1.2.4.3 Weaknesses & Competitive Threats
15.1.3 GE Healthcare
15.1.3.1 Business Overview
15.1.3.2 Products Offered
15.1.3.3 Recent Developments
15.1.3.3.1 Product Approvals
15.1.3.3.2 Deals
15.1.3.3.3 Expansions
15.1.3.3.4 Other Developments
15.1.3.4 Analyst's View
15.1.3.4.1 Right to Win
15.1.3.4.2 Strategic Choices
15.1.3.4.3 Weaknesses & Competitive Threats
15.1.4 Curium
15.1.4.1 Business Overview
15.1.4.2 Products Offered
15.1.4.3 Recent Developments
15.1.4.3.1 Product Approvals & Enhancements
15.1.4.3.2 Deals
15.1.4.3.3 Expansions
15.1.4.3.4 Other Developments
15.1.4.4 Analyst's View
15.1.4.4.1 Right to Win
15.1.4.4.2 Strategic Choices
15.1.4.4.3 Weaknesses & Competitive Threats
15.1.5 Telix Pharmaceuticals Limited
15.1.5.1 Business Overview
15.1.5.2 Products Offered
15.1.5.3 Recent Developments
15.1.5.3.1 Product Approvals
15.1.5.3.2 Deals
15.1.5.3.3 Other Developments
15.1.5.4 Analyst's View
15.1.5.4.1 Right to Win
15.1.5.4.2 Strategic Choices
15.1.5.4.3 Weaknesses & Competitive Threats
15.1.6 Siemens Healthineers
15.1.6.1 Business Overview
15.1.6.2 Products Offered
15.1.6.3 Recent Developments
15.1.6.3.1 Deals
15.1.6.3.2 Other Developments
15.1.7 China Isotope & Radiation Corporation
15.1.7.1 Business Overview
15.1.7.2 Products Offered
15.1.7.3 Recent Developments
15.1.7.3.1 Other Developments
15.1.8 Bayer AG
15.1.8.1 Business Overview
15.1.8.2 Products Offered
15.1.8.3 Recent Developments
15.1.8.3.1 Deals
15.1.9 Bracco Imaging S.P.A.
15.1.9.1 Business Overview
15.1.9.2 Products Offered
15.1.9.3 Recent Developments
15.1.9.3.1 Product Approvals
15.1.9.3.2 Deals
15.1.9.3.3 Other Developments
15.1.10 Cardinal Health
15.1.10.1 Business Overview
15.1.10.2 Products Offered
15.1.10.3 Recent Developments
15.1.10.3.1 Deals
15.1.11 Jubilant Pharmova Limited
15.1.11.1 Business Overview
15.1.11.2 Products Offered
15.1.11.3 Recent Developments
15.1.11.3.1 Product Approvals
15.1.11.3.2 Deals
15.1.11.3.3 Other Developments
15.1.12 Eli Lilly and Company
15.1.12.1 Business Overview
15.1.12.2 Products Offered
15.1.12.3 Recent Developments
15.1.12.3.1 Deals
15.1.12.3.2 Other Developments
15.1.13 Bwxt Medical Ltd.
15.1.13.1 Business Overview
15.1.13.2 Products Offered
15.1.13.3 Recent Developments
15.1.13.3.1 Product Approvals
15.1.14 Ntp Radioisotopes Soc Ltd. (A Subsidiary of South African Nuclear Energy Corporation)
15.1.14.1 Business Overview
15.1.14.2 Products Offered
15.1.14.3 Recent Developments
15.1.14.3.1 Deals
15.1.15 Eckert & Ziegler
15.1.15.1 Business Overview
15.1.15.2 Products Offered
15.1.15.3 Recent Developments
15.1.15.3.1 Product Approvals
15.1.15.3.2 Deals
15.1.15.3.3 Expansions
15.1.16 Isotope Jsc
15.1.16.1 Business Overview
15.1.16.2 Products Offered
15.1.16.3 Recent Developments
15.1.16.3.1 Deals
15.1.16.3.2 Other Developments
15.1.17 Pdradiopharma Inc.
15.1.17.1 Business Overview
15.1.17.2 Products Offered
15.1.17.3 Recent Developments
15.1.17.3.1 Product Launches & Approvals
15.1.17.3.2 Deals
15.1.17.3.3 Expansions
15.1.18 Itm Isotope Technologies Munich SE
15.1.18.1 Business Overview
15.1.18.2 Products Offered
15.1.18.3 Recent Developments
15.1.18.3.1 Product Approvals
15.1.18.3.2 Deals
15.1.18.3.3 Expansions
15.1.18.3.4 Other Developments
15.1.19 Narodowe Centrum Badan Jadrowych Osrodek Radioizotopów - Polatom
15.1.19.1 Business Overview
15.1.19.2 Products Offered
15.1.19.3 Recent Developments
15.1.19.3.1 Deals
15.1.20 Ansto
15.1.20.1 Business Overview
15.1.20.2 Products Offered
15.1.20.3 Recent Developments
15.1.20.3.1 Deals
15.1.20.3.2 Other Developments
15.2 Other Players
15.2.1 Shine Technologies, LLC
15.2.2 Isotopia Molecular Imaging Ltd.
15.2.3 Institute of Isotopes
15.2.4 Global Medical Solutions
15.2.5 Isotex Diagnostics
15.1.1 Novartis AG
15.1.1.1 Business Overview
15.1.1.2 Products Offered
15.1.1.3 Recent Developments
15.1.1.3.1 Product Approvals
15.1.1.3.2 Deals
15.1.1.3.3 Expansions
15.1.1.4 Analyst's View
15.1.1.4.1 Right to Win
15.1.1.4.2 Strategic Choices
15.1.1.4.3 Weaknesses & Competitive Threats
15.1.2 Lantheus Holdings, Inc.
15.1.2.1 Business Overview
15.1.2.2 Products Offered
15.1.2.3 Recent Developments
15.1.2.3.1 Deals
15.1.2.4 Analyst's View
15.1.2.4.1 Right to Win
15.1.2.4.2 Strategic Choices
15.1.2.4.3 Weaknesses & Competitive Threats
15.1.3 GE Healthcare
15.1.3.1 Business Overview
15.1.3.2 Products Offered
15.1.3.3 Recent Developments
15.1.3.3.1 Product Approvals
15.1.3.3.2 Deals
15.1.3.3.3 Expansions
15.1.3.3.4 Other Developments
15.1.3.4 Analyst's View
15.1.3.4.1 Right to Win
15.1.3.4.2 Strategic Choices
15.1.3.4.3 Weaknesses & Competitive Threats
15.1.4 Curium
15.1.4.1 Business Overview
15.1.4.2 Products Offered
15.1.4.3 Recent Developments
15.1.4.3.1 Product Approvals & Enhancements
15.1.4.3.2 Deals
15.1.4.3.3 Expansions
15.1.4.3.4 Other Developments
15.1.4.4 Analyst's View
15.1.4.4.1 Right to Win
15.1.4.4.2 Strategic Choices
15.1.4.4.3 Weaknesses & Competitive Threats
15.1.5 Telix Pharmaceuticals Limited
15.1.5.1 Business Overview
15.1.5.2 Products Offered
15.1.5.3 Recent Developments
15.1.5.3.1 Product Approvals
15.1.5.3.2 Deals
15.1.5.3.3 Other Developments
15.1.5.4 Analyst's View
15.1.5.4.1 Right to Win
15.1.5.4.2 Strategic Choices
15.1.5.4.3 Weaknesses & Competitive Threats
15.1.6 Siemens Healthineers
15.1.6.1 Business Overview
15.1.6.2 Products Offered
15.1.6.3 Recent Developments
15.1.6.3.1 Deals
15.1.6.3.2 Other Developments
15.1.7 China Isotope & Radiation Corporation
15.1.7.1 Business Overview
15.1.7.2 Products Offered
15.1.7.3 Recent Developments
15.1.7.3.1 Other Developments
15.1.8 Bayer AG
15.1.8.1 Business Overview
15.1.8.2 Products Offered
15.1.8.3 Recent Developments
15.1.8.3.1 Deals
15.1.9 Bracco Imaging S.P.A.
15.1.9.1 Business Overview
15.1.9.2 Products Offered
15.1.9.3 Recent Developments
15.1.9.3.1 Product Approvals
15.1.9.3.2 Deals
15.1.9.3.3 Other Developments
15.1.10 Cardinal Health
15.1.10.1 Business Overview
15.1.10.2 Products Offered
15.1.10.3 Recent Developments
15.1.10.3.1 Deals
15.1.11 Jubilant Pharmova Limited
15.1.11.1 Business Overview
15.1.11.2 Products Offered
15.1.11.3 Recent Developments
15.1.11.3.1 Product Approvals
15.1.11.3.2 Deals
15.1.11.3.3 Other Developments
15.1.12 Eli Lilly and Company
15.1.12.1 Business Overview
15.1.12.2 Products Offered
15.1.12.3 Recent Developments
15.1.12.3.1 Deals
15.1.12.3.2 Other Developments
15.1.13 Bwxt Medical Ltd.
15.1.13.1 Business Overview
15.1.13.2 Products Offered
15.1.13.3 Recent Developments
15.1.13.3.1 Product Approvals
15.1.14 Ntp Radioisotopes Soc Ltd. (A Subsidiary of South African Nuclear Energy Corporation)
15.1.14.1 Business Overview
15.1.14.2 Products Offered
15.1.14.3 Recent Developments
15.1.14.3.1 Deals
15.1.15 Eckert & Ziegler
15.1.15.1 Business Overview
15.1.15.2 Products Offered
15.1.15.3 Recent Developments
15.1.15.3.1 Product Approvals
15.1.15.3.2 Deals
15.1.15.3.3 Expansions
15.1.16 Isotope Jsc
15.1.16.1 Business Overview
15.1.16.2 Products Offered
15.1.16.3 Recent Developments
15.1.16.3.1 Deals
15.1.16.3.2 Other Developments
15.1.17 Pdradiopharma Inc.
15.1.17.1 Business Overview
15.1.17.2 Products Offered
15.1.17.3 Recent Developments
15.1.17.3.1 Product Launches & Approvals
15.1.17.3.2 Deals
15.1.17.3.3 Expansions
15.1.18 Itm Isotope Technologies Munich SE
15.1.18.1 Business Overview
15.1.18.2 Products Offered
15.1.18.3 Recent Developments
15.1.18.3.1 Product Approvals
15.1.18.3.2 Deals
15.1.18.3.3 Expansions
15.1.18.3.4 Other Developments
15.1.19 Narodowe Centrum Badan Jadrowych Osrodek Radioizotopów - Polatom
15.1.19.1 Business Overview
15.1.19.2 Products Offered
15.1.19.3 Recent Developments
15.1.19.3.1 Deals
15.1.20 Ansto
15.1.20.1 Business Overview
15.1.20.2 Products Offered
15.1.20.3 Recent Developments
15.1.20.3.1 Deals
15.1.20.3.2 Other Developments
15.2 Other Players
15.2.1 Shine Technologies, LLC
15.2.2 Isotopia Molecular Imaging Ltd.
15.2.3 Institute of Isotopes
15.2.4 Global Medical Solutions
15.2.5 Isotex Diagnostics
16 Research Methodology
16.1 Research Data
16.2 Research Approach
16.2.1 Secondary Research
16.2.1.1 Key Data from Secondary Sources
16.2.2 Primary Research
16.2.2.1 Primary Sources
16.2.2.2 Key Data from Primary Sources
16.2.2.3 Breakdown of Primaries
16.2.2.4 Insights from Primary Experts
16.3 Research Methodology Design
16.4 Market Size Estimation
16.4.1 Approach 1: Revenue Share Analysis (Bottom-Up Approach - Supply-Side Analysis)
16.4.2 Approach 2: Secondary Data & Primary Interviews
16.4.3 Approach 3: Segmental Market Size Assessment
16.4.4 Approach 4: Top-Down Approach
16.4.5 Growth Forecast
16.4.6 Geographic Market Assessment (By Region and Country)
16.5 Market Breakdown & Data Triangulation
16.6 Study Assumptions
16.7 Research Limitations
16.7.1 Methodology-Related Limitations
16.7.2 Scope-Related Limitations
16.8 Risk Assessment
16.2 Research Approach
16.2.1 Secondary Research
16.2.1.1 Key Data from Secondary Sources
16.2.2 Primary Research
16.2.2.1 Primary Sources
16.2.2.2 Key Data from Primary Sources
16.2.2.3 Breakdown of Primaries
16.2.2.4 Insights from Primary Experts
16.3 Research Methodology Design
16.4 Market Size Estimation
16.4.1 Approach 1: Revenue Share Analysis (Bottom-Up Approach - Supply-Side Analysis)
16.4.2 Approach 2: Secondary Data & Primary Interviews
16.4.3 Approach 3: Segmental Market Size Assessment
16.4.4 Approach 4: Top-Down Approach
16.4.5 Growth Forecast
16.4.6 Geographic Market Assessment (By Region and Country)
16.5 Market Breakdown & Data Triangulation
16.6 Study Assumptions
16.7 Research Limitations
16.7.1 Methodology-Related Limitations
16.7.2 Scope-Related Limitations
16.8 Risk Assessment
17 Appendix
17.1 Discussion Guide
17.2 Knowledgestore: The Subscription Portal
17.3 Customization Options
17.2 Knowledgestore: The Subscription Portal
17.3 Customization Options
List of Tables
Table 1 Exchange Rates Utilized for Conversion to USD
Table 2 Main Mo-99 Production Reactors
Table 3 Radiopharmaceuticals: Physical Half-Life and Major Clinical Applications
Table 4 UK: Nuclear Medicine-Related Workforce and Vacancy Data, 2021
Table 5 Nuclear Medicine Market: Porter's Five Forces Analysis
Table 6 Nuclear Medicine Market: Role in Ecosystem
Table 7 Indicative Price of Nuclear Medicine Products, by Type, 2024
Table 8 Indicative Price of Nuclear Medicine in Eastern Europe, by Type, 2024
Table 9 Indicative Price of Nuclear Medicine in Menat Region, by Type, 2024
Table 10 Average Selling Price of Radiopharmaceuticals in India, by Type, 2024
Table 11 Import Value for HS Code 2844, 2020-2024 (USD Thousand)
Table 12 Export Value for HS Code 2844, 2020-2024 (USD Thousand)
Table 13 Import Value for HS Code 3002, 2020-2024 (USD Thousand)
Table 14 Export Value for HS Code 3002, 2020-2024 (USD Thousand)
Table 15 Nuclear Medicine Market: Key Conferences & Events, 2026-2027
Table 16 Case 1: Beta-Amyloid Pet/CT Imaging Enables Alzheimer's Patient Qualification for Anti-Amyloid Therapy at New York-Presbyterian Hospital
Table 17 Case 2: Whole-Body Pet/CT with Extended Axial Fov Enables Detection of Rare Pericardial Recurrence in Pleural Mesothelioma at Rigshospitalet
Table 18 Case 3: Clinical and Operational Impact of Implementing an Integrated Theranostics Program in Brazil
Table 19 US-Adjusted Reciprocal Tariff Rates
Table 20 Jurisdiction Analysis of Top Applicant Countries for Nuclear Medicine Market
Table 21 Nuclear Medicine Market: List of Patents/Patent Applications
Table 22 North America: Regulatory Bodies, Government Agencies, and Other Organizations
Table 23 Europe: Regulatory Bodies, Government Agencies, and Other Organizations
Table 24 Asia-Pacific: Regulatory Bodies, Government Agencies, and Other Organizations
Table 25 Latin America: Regulatory Bodies, Government Agencies, and Other Organizations
Table 26 Middle East & Africa: Regulatory Bodies, Government Agencies, and Other Organizations
Table 27 Regulatory Scenario of North America
Table 28 Regulatory Scenario of Europe
Table 29 Regulatory Scenario of Asia-Pacific
Table 30 Regulatory Scenario of Latin America
Table 31 Regulatory Scenario of Middle East & Africa
Table 32 Influence of Stakeholders on Buying Process of Top Three End-users (%)
Table 33 Key Buying Criteria for Top Three End-users
Table 34 Unmet Needs in Nuclear Medicine Market
Table 35 End-user Expectations in Nuclear Medicine Market
Table 36 Nuclear Medicine Market, by Type, 2023-2030 (USD Million)
Table 37 Diagnostic Nuclear Medicine Market, by Type, 2023-2030 (USD Million)
Table 38 Diagnostic Nuclear Medicine Market, by Region, 2023-2030 (USD Million)
Table 39 Alternatives to Common Tc-99M-based Diagnostic Procedures due to Severe Tc-99M Shortages
Table 40 Spect Radiopharmaceuticals Market, by Type, 2023-2030 (USD Million)
Table 41 Spect Radiopharmaceuticals Market, by Region, 2023-2030 (USD Million)
Table 42 Tc-99M Market, by Region, 2023-2030 (USD Million)
Table 43 I-123 Market, by Region, 2023-2030 (USD Million)
Table 44 Ti-201 Market, by Region, 2023-2030 (USD Million)
Table 45 Ga-67 Market, by Region, 2023-2030 (USD Million)
Table 46 Other Spect Radiopharmaceuticals Market, by Region, 2023-2030 (USD Million)
Table 47 Pet Radiopharmaceuticals Market, by Type, 2023-2030 (USD Million)
Table 48 Pet Radiopharmaceuticals Market, by Region, 2023-2030 (USD Million)
Table 49 F-18 Market, by Region, 2023-2030 (USD Million)
Table 50 Rb-82 Market, by Region, 2023-2030 (USD Million)
Table 51 Other Pet Radiopharmaceuticals Market, by Region, 2023-2030 (USD Million)
Table 52 Therapeutic Nuclear Medicine Market, by Type, 2023-2030 (USD Million)
Table 53 Therapeutic Nuclear Medicine Market, by Region, 2023-2030 (USD Million)
Table 54 Alpha Emitters Market, by Type, 2023-2030 (USD Million)
Table 55 Ra-223 Market, by Region, 2023-2030 (USD Million)
Table 56 Beta Emitters Market, by Type, 2023-2030 (USD Million)
Table 57 Beta Emitters Market, by Region, 2023-2030 (USD Million)
Table 58 I-131 Market, by Region, 2023-2030 (USD Million)
Table 59 Y-90 Market, by Region, 2023-2030 (USD Million)
Table 60 Sm-153 Market, by Region, 2023-2030 (USD Million)
Table 61 Lu-177 Market, by Region, 2023-2030 (USD Million)
Table 62 Other Beta Emitters Market, by Region, 2023-2030 (USD Million)
Table 63 Brachytherapy Isotopes Market, by Type, 2023-2030 (USD Million)
Table 64 Brachytherapy Isotopes Market, by Region, 2023-2030 (USD Million)
Table 65 I-125 Market, by Region, 2023-2030 (USD Million)
Table 66 Ir-192 Market, by Region, 2023-2030 (USD Million)
Table 67 Pd-103 Market, by Region, 2023-2030 (USD Million)
Table 68 Cs-131 Market, by Region, 2023-2030 (USD Million)
Table 69 Other Brachytherapy Isotopes Market, by Region, 2023-2030 (USD Million)
Table 70 Nuclear Medicine Market, by Application, 2023-2030 (USD Million)
Table 71 Nuclear Medicine Market for Diagnostic Applications, by Type, 2023-2030 (USD Million)
Table 72 Nuclear Medicine Market for Diagnostic Applications, by Region, 2023-2030 (USD Million)
Table 73 Nuclear Medicine Market for Spect Applications, by Type, 2023-2030 (USD Million)
Table 74 Nuclear Medicine Market for Spect Applications, by Region, 2023-2030 (USD Million)
Table 75 Nuclear Medicine Market for Spect Cardiology Applications, by Region, 2023-2030 (USD Million)
Table 76 Nuclear Medicine Market for Spect Bone Scan Applications, by Region, 2023-2030 (USD Million)
Table 77 Nuclear Medicine Market for Spect Thyroid Applications, by Region, 2023-2030 (USD Million)
Table 78 Nuclear Medicine Market for Spect Pulmonary Scan Applications, by Region, 2023-2030 (USD Million)
Table 79 Nuclear Medicine Market for Other Spect Applications, by Region, 2023-2030 (USD Million)
Table 80 Nuclear Medicine Market for Pet Applications, by Type, 2023-2030 (USD Million)
Table 81 Nuclear Medicine Market for Pet Applications, by Region, 2023-2030 (USD Million)
Table 82 Nuclear Medicine Market for Pet Oncology Applications, by Region, 2023-2030 (USD Million)
Table 83 Nuclear Medicine Market for Pet Cardiology Applications, by Region, 2023-2030 (USD Million)
Table 84 Nuclear Medicine Market for Pet Neurology Applications, by Region, 2023-2030 (USD Million)
Table 85 Nuclear Medicine Market for Other Pet Applications, by Region, 2023-2030 (USD Million)
Table 86 Nuclear Medicine Market for Therapeutic Applications, by Type, 2023-2030 (USD Million)
Table 87 Nuclear Medicine Market for Therapeutic Applications, by Region, 2023-2030 (USD Million)
Table 88 Nuclear Medicine Market for Thyroid Indications, by Region, 2023-2030 (USD Million)
Table 89 Nuclear Medicine Market for Bone Metastasis Applications, by Region, 2023-2030 (USD Million)
Table 90 Nuclear Medicine Market for Endocrine Tumor Applications, by Region, 2023-2030 (USD Million)
Table 91 Nuclear Medicine Market for Lymphoma Applications, by Region, 2023-2030 (USD Million)
Table 92 Nuclear Medicine Market for Other Therapeutic Applications, by Region, 2023-2030 (USD Million)
Table 93 Nuclear Medicine Market, by Procedure, 2023-2030 (Thousand Procedures)
Table 94 Nuclear Medicine Market, by Region, 2023-2030 (Thousand Procedures)
Table 95 Nuclear Medicine Market for Diagnostic Procedures, by Type, 2023-2030 (Thousand Procedures)
Table 96 Nuclear Medicine Market for Diagnostic Procedures, by Region, 2023-2030 (Thousand Procedures)
Table 97 Nuclear Medicine Market for Therapeutic Procedures, by Region, 2023-2030 (Thousand Procedures)
Table 98 Nuclear Medicine Market, by End-user, 2023-2030 (USD Million)
Table 99 Nuclear Medicine Market for Hospitals, by Region, 2023-2030 (USD Million)
Table 100 Nuclear Medicine Market for Diagnostic & Imaging Centers, by Region, 2023-2030 (USD Million)
Table 101 Nuclear Medicine Market for Academic & Research Institutes, by Region, 2023-2030 (USD Million)
Table 102 Nuclear Medicine Market for Other End-users, by Region, 2023-2030 (USD Million)
Table 103 Nuclear Medicine Market, by Region, 2023-2030 (USD Million)
Table 104 North America: Key Macroeconomic Indicators
Table 105 North America: Nuclear Medicine Market, by Country, 2023-2030 (USD Million)
Table 106 North America: Nuclear Medicine Market, by Type, 2023-2030 (USD Million)
Table 107 North America: Diagnostic Nuclear Medicine Market, by Type, 2023-2030 (USD Million)
Table 108 North America: Nuclear Medicine Market for Spect Radiopharmaceuticals, by Type, 2023-2030 (USD Million)
Table 109 North America: Nuclear Medicine Market for Pet Radiopharmaceuticals, by Type, 2023-2030 (USD Million)
Table 110 North America: Therapeutic Nuclear Medicine Market, by Type, 2023-2030 (USD Million)
Table 111 North America: Nuclear Medicine Market for Beta Emitters, by Type, 2023-2030 (USD Million)
Table 112 North America: Nuclear Medicine Market for Brachytherapy Isotopes, by Type, 2023-2030 (USD Million)
Table 113 North America: Nuclear Medicine Market, by Application, 2023-2030 (USD Million)
Table 114 North America: Nuclear Medicine Market for Diagnostic Applications, by Type, 2023-2030 (USD Million)
Table 115 North America: Nuclear Medicine Market for Spect Applications, by Type, 2023-2030 (USD Million)
Table 116 North America: Nuclear Medicine Market for Pet Applications, by Type, 2023-2030 (USD Million)
Table 117 North America: Nuclear Medicine Market for Therapeutic Applications, by Type, 2023-2030 (USD Million)
Table 118 North America: Nuclear Medicine Market, by End-user, 2023-2030 (USD Million)
Table 119 US: Cancer Incidence, by Cancer Type, 2020 vs. 2040
Table 120 US: Nuclear Medicine Market, by Type, 2023-2030 (USD Million)
Table 121 US: Diagnostic Nuclear Medicine Market, by Type, 2023-2030 (USD Million)
Table 122 US: Nuclear Medicine Market for Spect Radiopharmaceuticals, by Type, 2023-2030 (USD Million)
Table 123 US: Nuclear Medicine Market for Pet Radiopharmaceuticals, by Type, 2023-2030 (USD Million)
Table 124 US: Therapeutic Nuclear Medicine Market, by Type, 2023-2030 (USD Million)
Table 125 US: Nuclear Medicine Market for Beta Emitters, by Type, 2023-2030 (USD Million)
Table 126 US: Nuclear Medicine Market for Brachytherapy Isotopes, by Type, 2023-2030 (USD Million)
Table 127 US: Nuclear Medicine Market, by Application, 2023-2030 (USD Million)
Table 128 US: Nuclear Medicine Market for Diagnostic Applications, by Type, 2023-2030 (USD Million)
Table 129 US: Nuclear Medicine Market for Spect Applications, by Type, 2023-2030 (USD Million)
Table 130 US: Nuclear Medicine Market for Pet Applications, by Type, 2023-2030 (USD Million)
Table 131 US: Nuclear Medicine Market for Therapeutic Applications, by Type, 2023-2030 (USD Million)
Table 132 US: Nuclear Medicine Market, by End-user, 2023-2030 (USD Million)
Table 133 Canada: Cancer Incidence, by Cancer Type, 2020 vs. 2040
Table 134 Canada: Nuclear Medicine Market, by Type, 2023-2030 (USD Million)
Table 135 Canada: Diagnostic Nuclear Medicine Market, by Type, 2023-2030 (USD Million)
Table 136 Canada: Nuclear Medicine Market for Spect Radiopharmaceuticals, by Type, 2023-2030 (USD Million)
Table 137 Canada: Nuclear Medicine Market for Pet Radiopharmaceuticals, by Type, 2023-2030 (USD Million)
Table 138 Canada: Therapeutic Nuclear Medicine Market, by Type, 2023-2030 (USD Million)
Table 139 Canada: Nuclear Medicine Market for Beta Emitters, by Type, 2023-2030 (USD Million)
Table 140 Canada: Nuclear Medicine Market for Brachytherapy Isotopes, by Type, 2023-2030 (USD Million)
Table 141 Canada: Nuclear Medicine Market, by Application, 2023-2030 (USD Million)
Table 142 Canada: Nuclear Medicine Market for Diagnostic Applications, by Type, 2023-2030 (USD Million)
Table 143 Canada: Nuclear Medicine Market for Spect Applications, by Type, 2023-2030 (USD Million)
Table 144 Canada: Nuclear Medicine Market for Pet Applications, by Type, 2023-2030 (USD Million)
Table 145 Canada: Nuclear Medicine Market for Therapeutic Applications, by Type, 2023-2030 (USD Million)
Table 146 Canada: Nuclear Medicine Market, by End-user, 2023-2030 (USD Million)
Table 147 Europe: Key Macroeconomic Indicators
Table 148 Europe: Nuclear Medicine Market, by Country, 2023-2030 (USD Million)
Table 149 Europe: Nuclear Medicine Market, by Type, 2023-2030 (USD Million)
Table 150 Europe: Diagnostic Nuclear Medicine Market, by Type, 2023-2030 (USD Million)
Table 151 Europe: Nuclear Medicine Market for Spect Radiopharmaceuticals, by Type, 2023-2030 (USD Million)
Table 152 Europe: Nuclear Medicine Market for Pet Radiopharmaceuticals, by Type, 2023-2030 (USD Million)
Table 153 Europe: Therapeutic Nuclear Medicine Market, by Type, 2023-2030 (USD Million)
Table 154 Europe: Nuclear Medicine Market for Beta Emitters, by Type, 2023-2030 (USD Million)
Table 155 Europe: Nuclear Medicine Market for Brachytherapy Isotopes, by Type, 2023-2030 (USD Million)
Table 156 Europe: Nuclear Medicine Market, by Application, 2023-2030 (USD Million)
Table 157 Europe: Nuclear Medicine Market for Diagnostic Applications, by Type, 2023-2030 (USD Million)
Table 158 Europe: Nuclear Medicine Market for Spect Applications, by Type, 2023-2030 (USD Million)
Table 159 Europe: Nuclear Medicine Market for Pet Applications, by Type, 2023-2030 (USD Million)
Table 160 Europe: Nuclear Medicine Market for Therapeutic Applications, by Type, 2023-2030 (USD Million)
Table 161 Europe: Nuclear Medicine Market, by End-user, 2023-2030 (USD Million)
Table 162 Germany: Nuclear Medicine Market, by Type, 2023-2030 (USD Million)
Table 163 Germany: Diagnostic Nuclear Medicine Market, by Type, 2023-2030 (USD Million)
Table 164 Germany: Nuclear Medicine Market for Spect Radiopharmaceuticals, by Type, 2023-2030 (USD Million)
Table 165 Germany: Nuclear Medicine Market for Pet Radiopharmaceuticals, by Type, 2023-2030 (USD Million)
Table 166 Germany: Therapeutic Nuclear Medicine Market, by Type, 2023-2030 (USD Million)
Table 167 Germany: Nuclear Medicine Market for Beta Emitters, by Type, 2023-2030 (USD Million)
Table 168 Germany: Nuclear Medicine Market for Brachytherapy Isotopes, by Type, 2023-2030 (USD Million)
Table 169 Germany: Nuclear Medicine Market, by Application, 2023-2030 (USD Million)
Table 170 Germany: Nuclear Medicine Market for Diagnostic Applications, by Type, 2023-2030 (USD Million)
Table 171 Germany: Nuclear Medicine Market for Spect Applications, by Type, 2023-2030 (USD Million)
Table 172 Germany: Nuclear Medicine Market for Pet Applications, by Type, 2023-2030 (USD Million)
Table 173 Germany: Nuclear Medicine Market for Therapeutic Applications, by Type, 2023-2030 (USD Million)
Table 174 Germany: Nuclear Medicine Market, by End-user, 2023-2030 (USD Million)
Table 175 France: Cancer Incidence, by Cancer Type, 2020 vs. 2040
Table 176 France: Nuclear Medicine Market, by Type, 2023-2030 (USD Million)
Table 177 France: Diagnostic Nuclear Medicine Market, by Type, 2023-2030 (USD Million)
Table 178 France: Nuclear Medicine Market for Spect Radiopharmaceuticals, by Type, 2023-2030 (USD Million)
Table 179 France: Nuclear Medicine Market for Pet Radiopharmaceuticals, by Type, 2023-2030 (USD Million)
Table 180 France: Therapeutic Nuclear Medicine Market, by Type, 2023-2030 (USD Million)
Table 181 France: Nuclear Medicine Market for Beta Emitters, by Type, 2023-2030 (USD Million)
Table 182 France: Nuclear Medicine Market for Brachytherapy Isotopes, by Type, 2023-2030 (USD Million)
Table 183 France: Nuclear Medicine Market, by Application, 2023-2030 (USD Million)
Table 184 France: Nuclear Medicine Market for Diagnostic Applications, by Type, 2023-2030 (USD Million)
Table 185 France: Nuclear Medicine Market for Spect Applications, by Type, 2023-2030 (USD Million)
Table 186 France: Nuclear Medicine Market for Pet Applications, by Type, 2023-2030 (USD Million)
Table 187 France: Nuclear Medicine Market for Therapeutic Applications, by Type, 2023-2030 (USD Million)
Table 188 France: Nuclear Medicine Market, by End-user, 2023-2030 (USD Million)
Table 189 UK: Nuclear Medicine Market, by Type, 2023-2030 (USD Million)
Table 190 UK: Diagnostic Nuclear Medicine Market, by Type, 2023-2030 (USD Million)
Table 191 UK: Nuclear Medicine Market for Spect Radiopharmaceuticals, by Type, 2023-2030 (USD Million)
Table 192 UK: Nuclear Medicine Market for Pet Radiopharmaceuticals, by Type, 2023-2030 (USD Million)
Table 193 UK: Therapeutic Nuclear Medicine Market, by Type, 2023-2030 (USD Million)
Table 194 UK: Nuclear Medicine Market for Beta Emitters, by Type, 2023-2030 (USD Million)
Table 195 UK: Nuclear Medicine Market for Brachytherapy Isotopes, by Type, 2023-2030 (USD Million)
Table 196 UK: Nuclear Medicine Market, by Application, 2023-2030 (USD Million)
Table 197 UK: Nuclear Medicine Market for Diagnostic Applications, by Type, 2023-2030 (USD Million)
Table 198 UK: Nuclear Medicine Market for Spect Applications, by Type, 2023-2030 (USD Million)
Table 199 UK: Nuclear Medicine Market for Pet Applications, by Type, 2023-2030 (USD Million)
Table 200 UK: Nuclear Medicine Market for Therapeutic Applications, by Type, 2023-2030 (USD Million)
Table 201 UK: Nuclear Medicine Market, by End-user, 2023-2030 (USD Million)
Table 202 Italy: Cancer Incidence, by Cancer Type, 2020 vs. 2040
Table 203 Italy: Nuclear Medicine Market, by Type, 2023-2030 (USD Million)
Table 204 Italy: Diagnostic Nuclear Medicine Market, by Type, 2023-2030 (USD Million)
Table 205 Italy: Nuclear Medicine Market for Spect Radiopharmaceuticals, by Type, 2023-2030 (USD Million)
Table 206 Italy: Nuclear Medicine Market for Pet Radiopharmaceuticals, by Type, 2023-2030 (USD Million)
Table 207 Italy: Therapeutic Nuclear Medicine Market, by Type, 2023-2030 (USD Million)
Table 208 Italy: Nuclear Medicine Market for Beta Emitters, by Type, 2023-2030 (USD Million)
Table 209 Italy: Nuclear Medicine Market for Brachytherapy Isotopes, by Type, 2023-2030 (USD Million)
Table 210 Italy: Nuclear Medicine Market, by Application, 2023-2030 (USD Million)
Table 211 Italy: Nuclear Medicine Market for Diagnostic Applications, by Type, 2023-2030 (USD Million)
Table 212 Italy: Nuclear Medicine Market for Spect Applications, by Type, 2023-2030 (USD Million)
Table 213 Italy: Nuclear Medicine Market for Pet Applications, by Type, 2023-2030 (USD Million)
Table 214 Italy: Nuclear Medicine Market for Therapeutic Applications, by Type, 2023-2030 (USD Million)
Table 215 Italy: Nuclear Medicine Market, by End-user, 2023-2030 (USD Million)
Table 216 Spain: Nuclear Medicine Market, by Type, 2023-2030 (USD Million)
Table 217 Spain: Diagnostic Nuclear Medicine Market, by Type, 2023-2030 (USD Million)
Table 218 Spain: Nuclear Medicine Market for Spect Radiopharmaceuticals, by Type, 2023-2030 (USD Million)
Table 219 Spain: Nuclear Medicine Market for Pet Radiopharmaceuticals, by Type, 2023-2030 (USD Million)
Table 220 Spain: Therapeutic Nuclear Medicine Market, by Type, 2023-2030 (USD Million)
Table 221 Spain: Nuclear Medicine Market for Beta Emitters, by Type, 2023-2030 (USD Million)
Table 222 Spain: Nuclear Medicine Market for Brachytherapy Isotopes, by Type, 2023-2030 (USD Million)
Table 223 Spain: Nuclear Medicine Market, by Application, 2023-2030 (USD Million)
Table 224 Spain: Nuclear Medicine Market for Diagnostic Applications, by Type, 2023-2030 (USD Million)
Table 225 Spain: Nuclear Medicine Market for Spect Applications, by Type, 2023-2030 (USD Million)
Table 226 Spain: Nuclear Medicine Market for Pet Applications, by Type, 2023-2030 (USD Million)
Table 227 Spain: Nuclear Medicine Market for Therapeutic Applications, by Type, 2023-2030 (USD Million)
Table 228 Spain: Nuclear Medicine Market, by End-user, 2023-2030 (USD Million)
Table 229 Rest of Europe: Nuclear Medicine Market, by Type, 2023-2030 (USD Million)
Table 230 Rest of Europe: Diagnostic Nuclear Medicine Market, by Type, 2023-2030 (USD Million)
Table 231 Rest of Europe: Nuclear Medicine Market for Spect Radiopharmaceuticals, by Type, 2023-2030 (USD Million)
Table 232 Rest of Europe: Nuclear Medicine Market for Pet Radiopharmaceuticals, by Type, 2023-2030 (USD Million)
Table 233 Rest of Europe: Therapeutic Nuclear Medicine Market, by Type, 2023-2030 (USD Million)
Table 234 Rest of Europe: Nuclear Medicine Market for Beta Emitters, by Type, 2023-2030 (USD Million)
Table 235 Rest of Europe: Nuclear Medicine Market for Brachytherapy Isotopes, by Type, 2023-2030 (USD Million)
Table 236 Rest of Europe: Nuclear Medicine Market, by Application, 2023-2030 (USD Million)
Table 237 Rest of Europe: Nuclear Medicine Market for Diagnostic Applications, by Type, 2023-2030 (USD Million)
Table 238 Rest of Europe: Nuclear Medicine Market for Spect Applications, by Type, 2023-2030 (USD Million)
Table 239 Rest of Europe: Nuclear Medicine Market for Pet Applications, by Type, 2023-2030 (USD Million)
Table 240 Rest of Europe: Nuclear Medicine Market for Therapeutic Applications, by Type, 2023-2030 (USD Million)
Table 241 Rest of Europe: Nuclear Medicine Market, by End-user, 2023-2030 (USD Million)
Table 242 Asia-Pacific: Key Macroeconomic Indicators
Table 243 Asia-Pacific: Nuclear Medicine Market, by Country, 2023-2030 (USD Million)
Table 244 Asia-Pacific: Nuclear Medicine Market, by Type, 2023-2030 (USD Million)
Table 245 Asia-Pacific: Diagnostic Nuclear Medicine Market, by Type, 2023-2030 (USD Million)
Table 246 Asia-Pacific: Nuclear Medicine Market for Spect Radiopharmaceuticals, by Type, 2023-2030 (USD Million)
Table 247 Asia-Pacific: Nuclear Medicine Market for Pet Radiopharmaceuticals, by Type, 2023-2030 (USD Million)
Table 248 Asia-Pacific: Therapeutic Nuclear Medicine Market, by Type, 2023-2030 (USD Million)
Table 249 Asia-Pacific: Nuclear Medicine Market for Beta Emitters, by Type, 2023-2030 (USD Million)
Table 250 Asia-Pacific: Nuclear Medicine Market for Brachytherapy Isotopes, by Type, 2023-2030 (USD Million)
Table 251 Asia-Pacific: Nuclear Medicine Market, by Application, 2023-2030 (USD Million)
Table 252 Asia-Pacific: Nuclear Medicine Market for Diagnostic Applications, by Type, 2023-2030 (USD Million)
Table 253 Asia-Pacific: Nuclear Medicine Market for Spect Applications, by Type, 2023-2030 (USD Million)
Table 254 Asia-Pacific: Nuclear Medicine Market for Pet Applications, by Type, 2023-2030 (USD Million)
Table 255 Asia-Pacific: Nuclear Medicine Market for Therapeutic Applications, by Type, 2023-2030 (USD Million)
Table 256 Asia-Pacific: Nuclear Medicine Market, by End-user, 2023-2030 (USD Million)
Table 257 Japan: Nuclear Medicine Market, by Type, 2023-2030 (USD Million)
Table 258 Japan: Diagnostic Nuclear Medicine Market, by Type, 2023-2030 (USD Million)
Table 259 Japan: Nuclear Medicine Market for Spect Radiopharmaceuticals, by Type, 2023-2030 (USD Million)
Table 260 Japan: Nuclear Medicine Market for Pet Radiopharmaceuticals, by Type, 2023-2030 (USD Million)
Table 261 Japan: Therapeutic Nuclear Medicine Market, by Type, 2023-2030 (USD Million)
Table 262 Japan: Nuclear Medicine Market for Beta Emitters, by Type, 2023-2030 (USD Million)
Table 263 Japan: Nuclear Medicine Market for Brachytherapy Isotopes, by Type, 2023-2030 (USD Million)
Table 264 Japan: Nuclear Medicine Market, by Application, 2023-2030 (USD Million)
Table 265 Japan: Nuclear Medicine Market for Diagnostic Applications, by Type, 2023-2030 (USD Million)
Table 266 Japan: Nuclear Medicine Market for Spect Applications, by Type, 2023-2030 (USD Million)
Table 267 Japan: Nuclear Medicine Market for Pet Applications, by Type, 2023-2030 (USD Million)
Table 268 Japan: Nuclear Medicine Market for Therapeutic Applications, by Type, 2023-2030 (USD Million)
Table 269 Japan: Nuclear Medicine Market, by End-user, 2023-2030 (USD Million)
Table 270 China: Cancer Incidence, by Cancer Type, 2020 vs. 2040
Table 271 China: Nuclear Medicine Market, by Type, 2023-2030 (USD Million)
Table 272 China: Diagnostic Nuclear Medicine Market, by Type, 2023-2030 (USD Million)
Table 273 China: Nuclear Medicine Market for Spect Radiopharmaceuticals, by Type, 2023-2030 (USD Million)
Table 274 China: Nuclear Medicine Market for Pet Radiopharmaceuticals, by Type, 2023-2030 (USD Million)
Table 275 China: Therapeutic Nuclear Medicine Market, by Type, 2023-2030 (USD Million)
Table 276 China: Nuclear Medicine Market for Beta Emitters, by Type, 2023-2030 (USD Million)
Table 277 China: Nuclear Medicine Market for Brachytherapy Isotopes, by Type, 2023-2030 (USD Million)
Table 278 China: Nuclear Medicine Market, by Application, 2023-2030 (USD Million)
Table 279 China: Nuclear Medicine Market for Diagnostic Applications, by Type, 2023-2030 (USD Million)
Table 280 China: Nuclear Medicine Market for Spect Applications, by Type, 2023-2030 (USD Million)
Table 281 China: Nuclear Medicine Market for Pet Applications, by Type, 2023-2030 (USD Million)
Table 282 China: Nuclear Medicine Market for Therapeutic Applications, by Type, 2023-2030 (USD Million)
Table 283 China: Nuclear Medicine Market, by End-user, 2023-2030 (USD Million)
Table 284 India: Nuclear Medicine Market, by Type, 2023-2030 (USD Million)
Table 285 India: Diagnostic Nuclear Medicine Market, by Type, 2023-2030 (USD Million)
Table 286 India: Nuclear Medicine Market for Spect Radiopharmaceuticals, by Type, 2023-2030 (USD Million)
Table 287 India: Nuclear Medicine Market for Pet Radiopharmaceuticals, by Type, 2023-2030 (USD Million)
Table 288 India: Therapeutic Nuclear Medicine Market, by Type, 2023-2030 (USD Million)
Table 289 India: Nuclear Medicine Market for Beta Emitters, by Type, 2023-2030 (USD Million)
Table 290 India: Nuclear Medicine Market for Brachytherapy Isotopes, by Type, 2023-2030 (USD Million)
Table 291 India: Nuclear Medicine Market, by Application, 2023-2030 (USD Million)
Table 292 India: Nuclear Medicine Market for Diagnostic Applications, by Type, 2023-2030 (USD Million)
Table 293 India: Nuclear Medicine Market for Spect Applications, by Type, 2023-2030 (USD Million)
Table 294 India: Nuclear Medicine Market for Pet Applications, by Type, 2023-2030 (USD Million)
Table 295 India: Nuclear Medicine Market for Therapeutic Applications, by Type, 2023-2030 (USD Million)
Table 296 India: Nuclear Medicine Market, by End-user, 2023-2030 (USD Million)
Table 297 South Korea: Nuclear Medicine Market, by Type, 2023-2030 (USD Million)
Table 298 South Korea: Diagnostic Nuclear Medicine Market, by Type, 2023-2030 (USD Million)
Table 299 South Korea: Nuclear Medicine Market for Spect Radiopharmaceuticals, by Type, 2023-2030 (USD Million)
Table 300 South Korea: Nuclear Medicine Market for Pet Radiopharmaceuticals, by Type, 2023-2030 (USD Million)
Table 301 South Korea: Therapeutic Nuclear Medicine Market, by Type, 2023-2030 (USD Million)
Table 302 South Korea: Nuclear Medicine Market for Beta Emitters, by Type, 2023-2030 (USD Million)
Table 303 South Korea: Nuclear Medicine Market for Brachytherapy Isotopes, by Type, 2023-2030 (USD Million)
Table 304 South Korea: Nuclear Medicine Market, by Application, 2023-2030 (USD Million)
Table 305 South Korea: Nuclear Medicine Market for Diagnostic Applications, by Type, 2023-2030 (USD Million)
Table 306 South Korea: Nuclear Medicine Market for Spect Applications, by Type, 2023-2030 (USD Million)
Table 307 South Korea: Nuclear Medicine Market for Pet Applications, by Type, 2023-2030 (USD Million)
Table 308 South Korea: Nuclear Medicine Market for Therapeutic Applications, by Type, 2023-2030 (USD Million)
Table 309 South Korea: Nuclear Medicine Market, by End-user, 2023-2030 (USD Million)
Table 310 Australia: Nuclear Medicine Market, by Type, 2023-2030 (USD Million)
Table 311 Australia: Diagnostic Nuclear Medicine Market, by Type, 2023-2030 (USD Million)
Table 312 Australia: Nuclear Medicine Market for Spect Radiopharmaceuticals, by Type, 2023-2030 (USD Million)
Table 313 Australia: Nuclear Medicine Market for Pet Radiopharmaceuticals, by Type, 2023-2030 (USD Million)
Table 314 Australia: Therapeutic Nuclear Medicine Market, by Type, 2023-2030 (USD Million)
Table 315 Australia: Nuclear Medicine Market for Beta Emitters, by Type, 2023-2030 (USD Million)
Table 316 Australia: Nuclear Medicine Market for Brachytherapy Isotopes, by Type, 2023-2030 (USD Million)
Table 317 Australia: Nuclear Medicine Market, by Application, 2023-2030 (USD Million)
Table 318 Australia: Nuclear Medicine Market for Diagnostic Applications, by Type, 2023-2030 (USD Million)
Table 319 Australia: Nuclear Medicine Market for Spect Applications, by Type, 2023-2030 (USD Million)
Table 320 Australia: Nuclear Medicine Market for Pet Applications, by Type, 2023-2030 (USD Million)
Table 321 Australia: Nuclear Medicine Market for Therapeutic Applications, by Type, 2023-2030 (USD Million)
Table 322 Australia: Nuclear Medicine Market, by End-user, 2023-2030 (USD Million)
Table 323 Rest of Asia-Pacific: Nuclear Medicine Market, by Type, 2023-2030 (USD Million)
Table 324 Rest of Asia-Pacific: Diagnostic Nuclear Medicine Market, by Type, 2023-2030 (USD Million)
Table 325 Rest of Asia-Pacific: Nuclear Medicine Market for Spect Radiopharmaceuticals, by Type, 2023-2030 (USD Million)
Table 326 Rest of Asia-Pacific: Nuclear Medicine Market for Pet Radiopharmaceuticals, by Type, 2023-2030 (USD Million)
Table 327 Rest of Asia-Pacific: Therapeutic Nuclear Medicine Market, by Type, 2023-2030 (USD Million)
Table 328 Rest of Asia-Pacific: Nuclear Medicine Market for Beta Emitters, by Type, 2023-2030 (USD Million)
Table 329 Rest of Asia-Pacific: Nuclear Medicine Market for Brachytherapy Isotopes, by Type, 2023-2030 (USD Million)
Table 330 Rest of Asia-Pacific: Nuclear Medicine Market, by Application, 2023-2030 (USD Million)
Table 331 Rest of Asia-Pacific: Nuclear Medicine Market for Diagnostic Applications, by Type, 2023-2030 (USD Million)
Table 332 Rest of Asia-Pacific: Nuclear Medicine Market for Spect Applications, by Type, 2023-2030 (USD Million)
Table 333 Rest of Asia-Pacific: Nuclear Medicine Market for Pet Applications, by Type, 2023-2030 (USD Million)
Table 334 Rest of Asia-Pacific: Nuclear Medicine Market for Therapeutic Applications, by Type, 2023-2030 (USD Million)
Table 335 Rest of Asia-Pacific: Nuclear Medicine Market, by End-user, 2023-2030 (USD Million)
Table 336 Latin America: Key Macroeconomic Indicators
Table 337 Latin America: Nuclear Medicine Market, by Country, 2023-2030 (USD Million)
Table 338 Latin America: Nuclear Medicine Market, by Type, 2023-2030 (USD Million)
Table 339 Latin America: Diagnostic Nuclear Medicine Market, by Type, 2023-2030 (USD Million)
Table 340 Latin America: Nuclear Medicine Market for Spect Radiopharmaceuticals, by Type, 2023-2030 (USD Million)
Table 341 Latin America: Nuclear Medicine Market for Pet Radiopharmaceuticals, by Type, 2023-2030 (USD Million)
Table 342 Latin America: Therapeutic Nuclear Medicine Market, by Type, 2023-2030 (USD Million)
Table 343 Latin America: Nuclear Medicine Market for Beta Emitters, by Type, 2023-2030 (USD Million)
Table 344 Latin America: Nuclear Medicine Market for Brachytherapy Isotopes, by Type, 2023-2030 (USD Million)
Table 345 Latin America: Nuclear Medicine Market, by Application, 2023-2030 (USD Million)
Table 346 Latin America: Nuclear Medicine Market for Diagnostic Applications, by Type, 2023-2030 (USD Million)
Table 347 Latin America: Nuclear Medicine Market for Spect Applications, by Type, 2023-2030 (USD Million)
Table 348 Latin America: Nuclear Medicine Market for Pet Applications, by Type, 2023-2030 (USD Million)
Table 349 Latin America: Nuclear Medicine Market for Therapeutic Applications, by Type, 2023-2030 (USD Million)
Table 350 Latin America: Nuclear Medicine Market, by End-user, 2023-2030 (USD Million)
Table 351 Brazil: Nuclear Medicine Market, by Type, 2023-2030 (USD Million)
Table 352 Brazil: Diagnostic Nuclear Medicine Market, by Type, 2023-2030 (USD Million)
Table 353 Brazil: Nuclear Medicine Market for Spect Radiopharmaceuticals, by Type, 2023-2030 (USD Million)
Table 354 Brazil: Nuclear Medicine Market for Pet Radiopharmaceuticals, by Type, 2023-2030 (USD Million)
Table 355 Brazil: Therapeutic Nuclear Medicine Market, by Type, 2023-2030 (USD Million)
Table 356 Brazil: Nuclear Medicine Market for Beta Emitters, by Type, 2023-2030 (USD Million)
Table 357 Brazil: Nuclear Medicine Market for Brachytherapy Isotopes, by Type, 2023-2030 (USD Million)
Table 358 Brazil: Nuclear Medicine Market, by Application, 2023-2030 (USD Million)
Table 359 Brazil: Nuclear Medicine Market for Diagnostic Applications, by Type, 2023-2030 (USD Million)
Table 360 Brazil: Nuclear Medicine Market for Spect Applications, by Type, 2023-2030 (USD Million)
Table 361 Brazil: Nuclear Medicine Market for Pet Applications, by Type, 2023-2030 (USD Million)
Table 362 Brazil: Nuclear Medicine Market for Therapeutic Applications, by Type, 2023-2030 (USD Million)
Table 363 Brazil: Nuclear Medicine Market, by End-user, 2023-2030 (USD Million)
Table 364 Mexico: Nuclear Medicine Market, by Type, 2023-2030 (USD Million)
Table 365 Mexico: Diagnostic Nuclear Medicine Market, by Type, 2023-2030 (USD Million)
Table 366 Mexico: Nuclear Medicine Market for Spect Radiopharmaceuticals, by Type, 2023-2030 (USD Million)
Table 367 Mexico: Nuclear Medicine Market for Pet Radiopharmaceuticals, by Type, 2023-2030 (USD Million)
Table 368 Mexico: Therapeutic Nuclear Medicine Market, by Type, 2023-2030 (USD Million)
Table 369 Mexico: Nuclear Medicine Market for Beta Emitters, by Type, 2023-2030 (USD Million)
Table 370 Mexico: Nuclear Medicine Market for Brachytherapy Isotopes, by Type, 2023-2030 (USD Million)
Table 371 Mexico: Nuclear Medicine Market, by Application, 2023-2030 (USD Million)
Table 372 Mexico: Nuclear Medicine Market for Diagnostic Applications, by Type, 2023-2030 (USD Million)
Table 373 Mexico: Nuclear Medicine Market for Spect Applications, by Type, 2023-2030 (USD Million)
Table 374 Mexico: Nuclear Medicine Market for Pet Applications, by Type, 2023-2030 (USD Million)
Table 375 Mexico: Nuclear Medicine Market for Therapeutic Applications, by Type, 2023-2030 (USD Million)
Table 376 Mexico: Nuclear Medicine Market, by End-user, 2023-2030 (USD Million)
Table 377 Rest of Latin America: Nuclear Medicine Market, by Type, 2023-2030 (USD Million)
Table 378 Rest of Latin America: Diagnostic Nuclear Medicine Market, by Type, 2023-2030 (USD Million)
Table 379 Rest of Latin America: Nuclear Medicine Market for Spect Radiopharmaceuticals, by Type, 2023-2030 (USD Million)
Table 380 Rest of Latin America: Nuclear Medicine Market for Pet Radiopharmaceuticals, by Type, 2023-2030 (USD Million)
Table 381 Rest of Latin America: Therapeutic Nuclear Medicine Market, by Type, 2023-2030 (USD Million)
Table 382 Rest of Latin America: Nuclear Medicine Market for Beta Emitters, by Type, 2023-2030 (USD Million)
Table 383 Rest of Latin America: Nuclear Medicine Market for Brachytherapy Isotopes, by Type, 2023-2030 (USD Million)
Table 384 Rest of Latin America: Nuclear Medicine Market, by Application, 2023-2030 (USD Million)
Table 385 Rest of Latin America: Nuclear Medicine Market for Diagnostic Applications, by Type, 2023-2030 (USD Million)
Table 386 Rest of Latin America: Nuclear Medicine Market for Spect Applications, by Type, 2023-2030 (USD Million)
Table 387 Rest of Latin America: Nuclear Medicine Market for Pet Applications, by Type, 2023-2030 (USD Million)
Table 388 Rest of Latin America: Nuclear Medicine Market for Therapeutic Applications, by Type, 2023-2030 (USD Million)
Table 389 Rest of Latin America: Nuclear Medicine Market, by End-user, 2023-2030 (USD Million)
Table 390 Middle East & Africa: Key Macroeconomic Indicators
Table 391 Middle East & Africa: Nuclear Medicine Market, by Region, 2023-2030 (USD Million)
Table 392 Middle East & Africa: Nuclear Medicine Market, by Type, 2023-2030 (USD Million)
Table 393 Middle East & Africa: Diagnostic Nuclear Medicine Market, by Type, 2023-2030 (USD Million)
Table 394 Middle East & Africa: Nuclear Medicine Market for Spect Radiopharmaceuticals, by Type, 2023-2030 (USD Million)
Table 395 Middle East & Africa: Nuclear Medicine Market for Pet Radiopharmaceuticals, by Type, 2023-2030 (USD Million)
Table 396 Middle East & Africa: Therapeutic Nuclear Medicine Market, by Type, 2023-2030 (USD Million)
Table 397 Middle East & Africa: Nuclear Medicine Market for Beta Emitters, by Type, 2023-2030 (USD Million)
Table 398 Middle East & Africa: Nuclear Medicine Market for Brachytherapy Isotopes, by Type, 2023-2030 (USD Million)
Table 399 Middle East & Africa: Nuclear Medicine Market, by Application, 2023-2030 (USD Million)
Table 400 Middle East & Africa: Nuclear Medicine Market for Diagnostic Applications, by Type, 2023-2030 (USD Million)
Table 401 Middle East & Africa: Nuclear Medicine Market for Spect Applications, by Type, 2023-2030 (USD Million)
Table 402 Middle East & Africa: Nuclear Medicine Market for Pet Applications, by Type, 2023-2030 (USD Million)
Table 403 Middle East & Africa: Nuclear Medicine Market for Therapeutic Applications, by Type, 2023-2030 (USD Million)
Table 404 Middle East & Africa: Nuclear Medicine Market, by End-user, 2023-2030 (USD Million)
Table 405 GCC Countries: Nuclear Medicine Market, by Type, 2023-2030 (USD Million)
Table 406 GCC Countries: Diagnostic Nuclear Medicine Market, by Type, 2023-2030 (USD Million)
Table 407 GCC Countries: Nuclear Medicine Market for Spect Radiopharmaceuticals, by Type, 2023-2030 (USD Million)
Table 408 GCC Countries: Nuclear Medicine Market for Pet Radiopharmaceuticals, by Type, 2023-2030 (USD Million)
Table 409 GCC Countries: Therapeutic Nuclear Medicine Market, by Type, 2023-2030 (USD Million)
Table 410 GCC Countries: Nuclear Medicine Market for Beta Emitters, by Type, 2023-2030 (USD Million)
Table 411 GCC Countries: Nuclear Medicine Market for Brachytherapy Isotopes, by Type, 2023-2030 (USD Million)
Table 412 GCC Countries: Nuclear Medicine Market, by Application, 2023-2030 (USD Million)
Table 413 GCC Countries: Nuclear Medicine Market for Diagnostic Applications, by Type, 2023-2030 (USD Million)
Table 414 GCC Countries: Nuclear Medicine Market for Spect Applications, by Type, 2023-2030 (USD Million)
Table 415 GCC Countries: Nuclear Medicine Market for Pet Applications, by Type, 2023-2030 (USD Million)
Table 416 GCC Countries: Nuclear Medicine Market for Therapeutic Applications, by Type, 2023-2030 (USD Million)
Table 417 GCC Countries: Nuclear Medicine Market, by End-user, 2023-2030 (USD Million)
Table 418 Rest of Middle East & Africa: Nuclear Medicine Market, by Type, 2023-2030 (USD Million)
Table 419 Rest of Middle East & Africa: Diagnostic Nuclear Medicine Market, by Type, 2023-2030 (USD Million)
Table 420 Rest of Middle East & Africa: Nuclear Medicine Market for Spect Radiopharmaceuticals, by Type, 2023-2030 (USD Million)
Table 421 Rest of Middle East & Africa: Nuclear Medicine Market for Pet Radiopharmaceuticals, by Type, 2023-2030 (USD Million)
Table 422 Rest of Middle East & Africa: Therapeutic Nuclear Medicine Market, by Type, 2023-2030 (USD Million)
Table 423 Rest of Middle East & Africa: Nuclear Medicine Market for Beta Emitters, by Type, 2023-2030 (USD Million)
Table 424 Rest of Middle East & Africa: Nuclear Medicine Market for Brachytherapy Isotopes, by Type, 2023-2030 (USD Million)
Table 425 Rest of Middle East & Africa: Nuclear Medicine Market, by Application, 2023-2030 (USD Million)
Table 426 Rest of Middle East & Africa: Nuclear Medicine Market for Diagnostic Applications, by Type, 2023-2030 (USD Million)
Table 427 Rest of Middle East & Africa: Nuclear Medicine Market for Spect Applications, by Type, 2023-2030 (USD Million)
Table 428 Rest of Middle East & Africa: Nuclear Medicine Market for Pet Applications, by Type, 2023-2030 (USD Million)
Table 429 Rest of Middle East & Africa: Nuclear Medicine Market for Therapeutic Applications, by Type, 2023-2030 (USD Million)
Table 430 Rest of Middle East & Africa: Nuclear Medicine Market, by End-user, 2023-2030 (USD Million)
Table 431 Overview of Strategies Adopted by Key Players in Nuclear Medicine, January 2022-December 2025
Table 432 Nuclear Medicine Market: Degree of Competition
Table 433 Nuclear Medicine Market: Region Footprint
Table 434 Nuclear Medicine Market: Type Footprint
Table 435 Nuclear Medicine Market: Application Footprint
Table 436 Nuclear Medicine Market: Detailed List of Key Startup/SME Players
Table 437 Nuclear Medicine Market: Competitive Benchmarking of Key Emerging Players/Startups, by Region
Table 438 Nuclear Medicine Market: Competitive Benchmarking of Key Emerging Players/Startups, by Type
Table 439 Nuclear Medicine Market: Competitive Benchmarking of Key Emerging Players/Startups, by Application
Table 440 Nuclear Medicine Market: Product Approvals, January 2022- December 2025
Table 441 Nuclear Medicine Market: Deals, January 2022-December 2025
Table 442 Nuclear Medicine Market: Expansions, January 2022-December 2025
Table 443 Nuclear Medicine Market: Other Developments, January 2022-December 2025
Table 444 Novartis AG: Company Overview
Table 445 Novartis AG: Products Offered
Table 446 Novartis AG: Product Approvals, January 2022-December 2025
Table 447 Novartis AG: Deals, January 2022-December 2025
Table 448 Novartis AG: Expansions, January 2022-December 2025
Table 449 Lantheus Holdings, Inc.: Company Overview
Table 450 Lantheus Holdings, Inc.: Products Offered
Table 451 Lantheus Holdings, Inc.: Deals, January 2022-December 2025
Table 452 GE Healthcare: Company Overview
Table 453 GE Healthcare: Products Offered
Table 454 GE Healthcare: Product Approvals, January 2022-December 2025
Table 455 GE Healthcare: Deals, January 2022-December 2025
Table 456 GE Healthcare: Expansions, January 2022-December 2025
Table 457 GE Healthcare: Other Developments, January 2022-December 2025
Table 458 Curium: Company Overview
Table 459 Curium: Products Offered
Table 460 Curium: Product Approvals & Enhancements, January 2022-December 2025
Table 461 Curium: Deals, January 2022-December 2025
Table 462 Curium: Expansions, January 2022-December 2025
Table 463 Curium: Other Developments, January 2022-December 2025
Table 464 Telix Pharmaceuticals Limited: Company Overview
Table 465 Telix Pharmaceuticals Limited: Products Offered
Table 466 Telix Pharmaceuticals Limited: Product Approvals, January 2022-December 2025
Table 467 Telix Pharmaceuticals Limited: Deals, January 2022-December 2025
Table 468 Telix Pharmaceuticals Limited: Other Developments, January 2022-December 2025
Table 469 Siemens Healthineers: Company Overview
Table 470 Siemens Healthineers: Products Offered
Table 471 Siemens Healthineers: Deals, January 2022-December 2025
Table 472 Siemens Healthineers: Other Developments, January 2022-December 2025
Table 473 China Isotope & Radiation Corporation: Company Overview
Table 474 China Isotope & Radiation Corporation: Products Offered
Table 475 China Isotope & Radiation Corporation: Other Developments, January 2022-December 2025
Table 476 Bayer AG: Company Overview
Table 477 Bayer AG: Products Offered
Table 478 Bayer AG: Deals, January 2022-December 2025
Table 479 Bracco Imaging S.P.A.: Company Overview
Table 480 Bracco Imaging S.P.A.: Products Offered
Table 481 Bracco Imaging S.P.A.: Product Approvals, January 2022-December 2025
Table 482 Bracco Imaging S.P.A.: Deals, January 2022-December 2025
Table 483 Bracco Imaging S.P.A.: Other Develeopments, January 2022-December 2025
Table 484 Cardinal Health: Company Overview
Table 485 Cardinal Health: Products Offered
Table 486 Cardinal Health: Deals, January 2022-December 2025
Table 487 Jubilant Pharmova Limited: Company Overview
Table 488 Jubilant Pharmova Limited: Products Offered
Table 489 Jubilant Pharmova Limited: Product Approvals, January 2022-December 2025
Table 490 Jubilant Pharmova Limited: Deals, January 2022-December 2025
Table 491 Jubilant Pharmova Limited: Other Developments, January 2022-December 2025
Table 492 Eli Lilly and Company: Company Overview
Table 493 Eli Lilly and Company: Products Offered
Table 494 Eli Lilly and Company: Deals, January 2022-December 2025
Table 495 Eli Lilly and Company: Other Developments, January 2022-December 2025
Table 496 Bwxt Medical Ltd.: Company Overview
Table 497 Bwxt Medical Ltd.: Products Offered
Table 498 Bwxt Medical Ltd.: Product Approvals, January 2022-December 2025
Table 499 Ntp Radioisotopes Soc Ltd.: Company Overview
Table 500 Ntp Radioisotopes Soc Ltd.: Products Offered
Table 501 Ntp Radioisotopes Soc Ltd.: Deals, January 2022-December 2025
Table 502 Eckert & Ziegler: Company Overview
Table 503 Eckert & Ziegler: Products Offered
Table 504 Eckert & Ziegler: Product Approvals, January 2022-December 2025
Table 505 Eckert & Ziegler: Deals, January 2022-December 2025
Table 506 Eckert & Ziegler: Expansions, January 2022-December 2025
Table 507 Joint Stock Company Isotope (Isotope Jsc): Company Overview
Table 508 Isotope Jsc: Products Offered
Table 509 Isotope Jsc: Deals, January 2022-December 2025
Table 510 Isotope Jsc: Other Developments, January 2022-December 2025
Table 511 Pdradiopharma Inc.: Company Overview
Table 512 Pdradiopharma Inc.: Products Offered
Table 513 Pdradiopharma Inc.: Product Launches & Approvals, January 2022-December 2025
Table 514 Pdradiopharma Inc.: Deals, January 2022-December 2025
Table 515 Pdradiopharma Inc.: Expansions, January 2022-December 2025
Table 516 Itm Isotope Technologies Munich SE: Company Overview
Table 517 Itm Isotope Technologies Munich SE: Products Offered
Table 518 Itm Isotope Technologies Munich SE: Product Approvals, January 2022-December 2025
Table 519 Itm Isotope Technologies Munich SE: Deals, January 2022-December 2025
Table 520 Itm Isotope Technologies Munich SE: Expansions, January 2022-December 2025
Table 521 Itm Isotope Technologies Munich SE: Other Developments, January 2022-December 2025
Table 522 Narodowe Centrum Badan Jadrowych Osrodek Radioizotopów - Polatom: Company Overview
Table 523 Narodowe Centrum Badan Jadrowych Osrodek Radioizotopów - Polatom: Products Offered
Table 524 Narodowe Centrum Badan Jadrowych Osrodek Radioizotopów - Polatom: Deals, January 2022-December 2025
Table 525 Ansto: Company Overview
Table 526 Ansto: Products Offered
Table 527 Ansto: Deals, January 2022-December 2025
Table 528 Ansto: Other Developments, January 2022-December 2025
Table 529 Risk Assessment: Nuclear Medicine Market
Table 2 Main Mo-99 Production Reactors
Table 3 Radiopharmaceuticals: Physical Half-Life and Major Clinical Applications
Table 4 UK: Nuclear Medicine-Related Workforce and Vacancy Data, 2021
Table 5 Nuclear Medicine Market: Porter's Five Forces Analysis
Table 6 Nuclear Medicine Market: Role in Ecosystem
Table 7 Indicative Price of Nuclear Medicine Products, by Type, 2024
Table 8 Indicative Price of Nuclear Medicine in Eastern Europe, by Type, 2024
Table 9 Indicative Price of Nuclear Medicine in Menat Region, by Type, 2024
Table 10 Average Selling Price of Radiopharmaceuticals in India, by Type, 2024
Table 11 Import Value for HS Code 2844, 2020-2024 (USD Thousand)
Table 12 Export Value for HS Code 2844, 2020-2024 (USD Thousand)
Table 13 Import Value for HS Code 3002, 2020-2024 (USD Thousand)
Table 14 Export Value for HS Code 3002, 2020-2024 (USD Thousand)
Table 15 Nuclear Medicine Market: Key Conferences & Events, 2026-2027
Table 16 Case 1: Beta-Amyloid Pet/CT Imaging Enables Alzheimer's Patient Qualification for Anti-Amyloid Therapy at New York-Presbyterian Hospital
Table 17 Case 2: Whole-Body Pet/CT with Extended Axial Fov Enables Detection of Rare Pericardial Recurrence in Pleural Mesothelioma at Rigshospitalet
Table 18 Case 3: Clinical and Operational Impact of Implementing an Integrated Theranostics Program in Brazil
Table 19 US-Adjusted Reciprocal Tariff Rates
Table 20 Jurisdiction Analysis of Top Applicant Countries for Nuclear Medicine Market
Table 21 Nuclear Medicine Market: List of Patents/Patent Applications
Table 22 North America: Regulatory Bodies, Government Agencies, and Other Organizations
Table 23 Europe: Regulatory Bodies, Government Agencies, and Other Organizations
Table 24 Asia-Pacific: Regulatory Bodies, Government Agencies, and Other Organizations
Table 25 Latin America: Regulatory Bodies, Government Agencies, and Other Organizations
Table 26 Middle East & Africa: Regulatory Bodies, Government Agencies, and Other Organizations
Table 27 Regulatory Scenario of North America
Table 28 Regulatory Scenario of Europe
Table 29 Regulatory Scenario of Asia-Pacific
Table 30 Regulatory Scenario of Latin America
Table 31 Regulatory Scenario of Middle East & Africa
Table 32 Influence of Stakeholders on Buying Process of Top Three End-users (%)
Table 33 Key Buying Criteria for Top Three End-users
Table 34 Unmet Needs in Nuclear Medicine Market
Table 35 End-user Expectations in Nuclear Medicine Market
Table 36 Nuclear Medicine Market, by Type, 2023-2030 (USD Million)
Table 37 Diagnostic Nuclear Medicine Market, by Type, 2023-2030 (USD Million)
Table 38 Diagnostic Nuclear Medicine Market, by Region, 2023-2030 (USD Million)
Table 39 Alternatives to Common Tc-99M-based Diagnostic Procedures due to Severe Tc-99M Shortages
Table 40 Spect Radiopharmaceuticals Market, by Type, 2023-2030 (USD Million)
Table 41 Spect Radiopharmaceuticals Market, by Region, 2023-2030 (USD Million)
Table 42 Tc-99M Market, by Region, 2023-2030 (USD Million)
Table 43 I-123 Market, by Region, 2023-2030 (USD Million)
Table 44 Ti-201 Market, by Region, 2023-2030 (USD Million)
Table 45 Ga-67 Market, by Region, 2023-2030 (USD Million)
Table 46 Other Spect Radiopharmaceuticals Market, by Region, 2023-2030 (USD Million)
Table 47 Pet Radiopharmaceuticals Market, by Type, 2023-2030 (USD Million)
Table 48 Pet Radiopharmaceuticals Market, by Region, 2023-2030 (USD Million)
Table 49 F-18 Market, by Region, 2023-2030 (USD Million)
Table 50 Rb-82 Market, by Region, 2023-2030 (USD Million)
Table 51 Other Pet Radiopharmaceuticals Market, by Region, 2023-2030 (USD Million)
Table 52 Therapeutic Nuclear Medicine Market, by Type, 2023-2030 (USD Million)
Table 53 Therapeutic Nuclear Medicine Market, by Region, 2023-2030 (USD Million)
Table 54 Alpha Emitters Market, by Type, 2023-2030 (USD Million)
Table 55 Ra-223 Market, by Region, 2023-2030 (USD Million)
Table 56 Beta Emitters Market, by Type, 2023-2030 (USD Million)
Table 57 Beta Emitters Market, by Region, 2023-2030 (USD Million)
Table 58 I-131 Market, by Region, 2023-2030 (USD Million)
Table 59 Y-90 Market, by Region, 2023-2030 (USD Million)
Table 60 Sm-153 Market, by Region, 2023-2030 (USD Million)
Table 61 Lu-177 Market, by Region, 2023-2030 (USD Million)
Table 62 Other Beta Emitters Market, by Region, 2023-2030 (USD Million)
Table 63 Brachytherapy Isotopes Market, by Type, 2023-2030 (USD Million)
Table 64 Brachytherapy Isotopes Market, by Region, 2023-2030 (USD Million)
Table 65 I-125 Market, by Region, 2023-2030 (USD Million)
Table 66 Ir-192 Market, by Region, 2023-2030 (USD Million)
Table 67 Pd-103 Market, by Region, 2023-2030 (USD Million)
Table 68 Cs-131 Market, by Region, 2023-2030 (USD Million)
Table 69 Other Brachytherapy Isotopes Market, by Region, 2023-2030 (USD Million)
Table 70 Nuclear Medicine Market, by Application, 2023-2030 (USD Million)
Table 71 Nuclear Medicine Market for Diagnostic Applications, by Type, 2023-2030 (USD Million)
Table 72 Nuclear Medicine Market for Diagnostic Applications, by Region, 2023-2030 (USD Million)
Table 73 Nuclear Medicine Market for Spect Applications, by Type, 2023-2030 (USD Million)
Table 74 Nuclear Medicine Market for Spect Applications, by Region, 2023-2030 (USD Million)
Table 75 Nuclear Medicine Market for Spect Cardiology Applications, by Region, 2023-2030 (USD Million)
Table 76 Nuclear Medicine Market for Spect Bone Scan Applications, by Region, 2023-2030 (USD Million)
Table 77 Nuclear Medicine Market for Spect Thyroid Applications, by Region, 2023-2030 (USD Million)
Table 78 Nuclear Medicine Market for Spect Pulmonary Scan Applications, by Region, 2023-2030 (USD Million)
Table 79 Nuclear Medicine Market for Other Spect Applications, by Region, 2023-2030 (USD Million)
Table 80 Nuclear Medicine Market for Pet Applications, by Type, 2023-2030 (USD Million)
Table 81 Nuclear Medicine Market for Pet Applications, by Region, 2023-2030 (USD Million)
Table 82 Nuclear Medicine Market for Pet Oncology Applications, by Region, 2023-2030 (USD Million)
Table 83 Nuclear Medicine Market for Pet Cardiology Applications, by Region, 2023-2030 (USD Million)
Table 84 Nuclear Medicine Market for Pet Neurology Applications, by Region, 2023-2030 (USD Million)
Table 85 Nuclear Medicine Market for Other Pet Applications, by Region, 2023-2030 (USD Million)
Table 86 Nuclear Medicine Market for Therapeutic Applications, by Type, 2023-2030 (USD Million)
Table 87 Nuclear Medicine Market for Therapeutic Applications, by Region, 2023-2030 (USD Million)
Table 88 Nuclear Medicine Market for Thyroid Indications, by Region, 2023-2030 (USD Million)
Table 89 Nuclear Medicine Market for Bone Metastasis Applications, by Region, 2023-2030 (USD Million)
Table 90 Nuclear Medicine Market for Endocrine Tumor Applications, by Region, 2023-2030 (USD Million)
Table 91 Nuclear Medicine Market for Lymphoma Applications, by Region, 2023-2030 (USD Million)
Table 92 Nuclear Medicine Market for Other Therapeutic Applications, by Region, 2023-2030 (USD Million)
Table 93 Nuclear Medicine Market, by Procedure, 2023-2030 (Thousand Procedures)
Table 94 Nuclear Medicine Market, by Region, 2023-2030 (Thousand Procedures)
Table 95 Nuclear Medicine Market for Diagnostic Procedures, by Type, 2023-2030 (Thousand Procedures)
Table 96 Nuclear Medicine Market for Diagnostic Procedures, by Region, 2023-2030 (Thousand Procedures)
Table 97 Nuclear Medicine Market for Therapeutic Procedures, by Region, 2023-2030 (Thousand Procedures)
Table 98 Nuclear Medicine Market, by End-user, 2023-2030 (USD Million)
Table 99 Nuclear Medicine Market for Hospitals, by Region, 2023-2030 (USD Million)
Table 100 Nuclear Medicine Market for Diagnostic & Imaging Centers, by Region, 2023-2030 (USD Million)
Table 101 Nuclear Medicine Market for Academic & Research Institutes, by Region, 2023-2030 (USD Million)
Table 102 Nuclear Medicine Market for Other End-users, by Region, 2023-2030 (USD Million)
Table 103 Nuclear Medicine Market, by Region, 2023-2030 (USD Million)
Table 104 North America: Key Macroeconomic Indicators
Table 105 North America: Nuclear Medicine Market, by Country, 2023-2030 (USD Million)
Table 106 North America: Nuclear Medicine Market, by Type, 2023-2030 (USD Million)
Table 107 North America: Diagnostic Nuclear Medicine Market, by Type, 2023-2030 (USD Million)
Table 108 North America: Nuclear Medicine Market for Spect Radiopharmaceuticals, by Type, 2023-2030 (USD Million)
Table 109 North America: Nuclear Medicine Market for Pet Radiopharmaceuticals, by Type, 2023-2030 (USD Million)
Table 110 North America: Therapeutic Nuclear Medicine Market, by Type, 2023-2030 (USD Million)
Table 111 North America: Nuclear Medicine Market for Beta Emitters, by Type, 2023-2030 (USD Million)
Table 112 North America: Nuclear Medicine Market for Brachytherapy Isotopes, by Type, 2023-2030 (USD Million)
Table 113 North America: Nuclear Medicine Market, by Application, 2023-2030 (USD Million)
Table 114 North America: Nuclear Medicine Market for Diagnostic Applications, by Type, 2023-2030 (USD Million)
Table 115 North America: Nuclear Medicine Market for Spect Applications, by Type, 2023-2030 (USD Million)
Table 116 North America: Nuclear Medicine Market for Pet Applications, by Type, 2023-2030 (USD Million)
Table 117 North America: Nuclear Medicine Market for Therapeutic Applications, by Type, 2023-2030 (USD Million)
Table 118 North America: Nuclear Medicine Market, by End-user, 2023-2030 (USD Million)
Table 119 US: Cancer Incidence, by Cancer Type, 2020 vs. 2040
Table 120 US: Nuclear Medicine Market, by Type, 2023-2030 (USD Million)
Table 121 US: Diagnostic Nuclear Medicine Market, by Type, 2023-2030 (USD Million)
Table 122 US: Nuclear Medicine Market for Spect Radiopharmaceuticals, by Type, 2023-2030 (USD Million)
Table 123 US: Nuclear Medicine Market for Pet Radiopharmaceuticals, by Type, 2023-2030 (USD Million)
Table 124 US: Therapeutic Nuclear Medicine Market, by Type, 2023-2030 (USD Million)
Table 125 US: Nuclear Medicine Market for Beta Emitters, by Type, 2023-2030 (USD Million)
Table 126 US: Nuclear Medicine Market for Brachytherapy Isotopes, by Type, 2023-2030 (USD Million)
Table 127 US: Nuclear Medicine Market, by Application, 2023-2030 (USD Million)
Table 128 US: Nuclear Medicine Market for Diagnostic Applications, by Type, 2023-2030 (USD Million)
Table 129 US: Nuclear Medicine Market for Spect Applications, by Type, 2023-2030 (USD Million)
Table 130 US: Nuclear Medicine Market for Pet Applications, by Type, 2023-2030 (USD Million)
Table 131 US: Nuclear Medicine Market for Therapeutic Applications, by Type, 2023-2030 (USD Million)
Table 132 US: Nuclear Medicine Market, by End-user, 2023-2030 (USD Million)
Table 133 Canada: Cancer Incidence, by Cancer Type, 2020 vs. 2040
Table 134 Canada: Nuclear Medicine Market, by Type, 2023-2030 (USD Million)
Table 135 Canada: Diagnostic Nuclear Medicine Market, by Type, 2023-2030 (USD Million)
Table 136 Canada: Nuclear Medicine Market for Spect Radiopharmaceuticals, by Type, 2023-2030 (USD Million)
Table 137 Canada: Nuclear Medicine Market for Pet Radiopharmaceuticals, by Type, 2023-2030 (USD Million)
Table 138 Canada: Therapeutic Nuclear Medicine Market, by Type, 2023-2030 (USD Million)
Table 139 Canada: Nuclear Medicine Market for Beta Emitters, by Type, 2023-2030 (USD Million)
Table 140 Canada: Nuclear Medicine Market for Brachytherapy Isotopes, by Type, 2023-2030 (USD Million)
Table 141 Canada: Nuclear Medicine Market, by Application, 2023-2030 (USD Million)
Table 142 Canada: Nuclear Medicine Market for Diagnostic Applications, by Type, 2023-2030 (USD Million)
Table 143 Canada: Nuclear Medicine Market for Spect Applications, by Type, 2023-2030 (USD Million)
Table 144 Canada: Nuclear Medicine Market for Pet Applications, by Type, 2023-2030 (USD Million)
Table 145 Canada: Nuclear Medicine Market for Therapeutic Applications, by Type, 2023-2030 (USD Million)
Table 146 Canada: Nuclear Medicine Market, by End-user, 2023-2030 (USD Million)
Table 147 Europe: Key Macroeconomic Indicators
Table 148 Europe: Nuclear Medicine Market, by Country, 2023-2030 (USD Million)
Table 149 Europe: Nuclear Medicine Market, by Type, 2023-2030 (USD Million)
Table 150 Europe: Diagnostic Nuclear Medicine Market, by Type, 2023-2030 (USD Million)
Table 151 Europe: Nuclear Medicine Market for Spect Radiopharmaceuticals, by Type, 2023-2030 (USD Million)
Table 152 Europe: Nuclear Medicine Market for Pet Radiopharmaceuticals, by Type, 2023-2030 (USD Million)
Table 153 Europe: Therapeutic Nuclear Medicine Market, by Type, 2023-2030 (USD Million)
Table 154 Europe: Nuclear Medicine Market for Beta Emitters, by Type, 2023-2030 (USD Million)
Table 155 Europe: Nuclear Medicine Market for Brachytherapy Isotopes, by Type, 2023-2030 (USD Million)
Table 156 Europe: Nuclear Medicine Market, by Application, 2023-2030 (USD Million)
Table 157 Europe: Nuclear Medicine Market for Diagnostic Applications, by Type, 2023-2030 (USD Million)
Table 158 Europe: Nuclear Medicine Market for Spect Applications, by Type, 2023-2030 (USD Million)
Table 159 Europe: Nuclear Medicine Market for Pet Applications, by Type, 2023-2030 (USD Million)
Table 160 Europe: Nuclear Medicine Market for Therapeutic Applications, by Type, 2023-2030 (USD Million)
Table 161 Europe: Nuclear Medicine Market, by End-user, 2023-2030 (USD Million)
Table 162 Germany: Nuclear Medicine Market, by Type, 2023-2030 (USD Million)
Table 163 Germany: Diagnostic Nuclear Medicine Market, by Type, 2023-2030 (USD Million)
Table 164 Germany: Nuclear Medicine Market for Spect Radiopharmaceuticals, by Type, 2023-2030 (USD Million)
Table 165 Germany: Nuclear Medicine Market for Pet Radiopharmaceuticals, by Type, 2023-2030 (USD Million)
Table 166 Germany: Therapeutic Nuclear Medicine Market, by Type, 2023-2030 (USD Million)
Table 167 Germany: Nuclear Medicine Market for Beta Emitters, by Type, 2023-2030 (USD Million)
Table 168 Germany: Nuclear Medicine Market for Brachytherapy Isotopes, by Type, 2023-2030 (USD Million)
Table 169 Germany: Nuclear Medicine Market, by Application, 2023-2030 (USD Million)
Table 170 Germany: Nuclear Medicine Market for Diagnostic Applications, by Type, 2023-2030 (USD Million)
Table 171 Germany: Nuclear Medicine Market for Spect Applications, by Type, 2023-2030 (USD Million)
Table 172 Germany: Nuclear Medicine Market for Pet Applications, by Type, 2023-2030 (USD Million)
Table 173 Germany: Nuclear Medicine Market for Therapeutic Applications, by Type, 2023-2030 (USD Million)
Table 174 Germany: Nuclear Medicine Market, by End-user, 2023-2030 (USD Million)
Table 175 France: Cancer Incidence, by Cancer Type, 2020 vs. 2040
Table 176 France: Nuclear Medicine Market, by Type, 2023-2030 (USD Million)
Table 177 France: Diagnostic Nuclear Medicine Market, by Type, 2023-2030 (USD Million)
Table 178 France: Nuclear Medicine Market for Spect Radiopharmaceuticals, by Type, 2023-2030 (USD Million)
Table 179 France: Nuclear Medicine Market for Pet Radiopharmaceuticals, by Type, 2023-2030 (USD Million)
Table 180 France: Therapeutic Nuclear Medicine Market, by Type, 2023-2030 (USD Million)
Table 181 France: Nuclear Medicine Market for Beta Emitters, by Type, 2023-2030 (USD Million)
Table 182 France: Nuclear Medicine Market for Brachytherapy Isotopes, by Type, 2023-2030 (USD Million)
Table 183 France: Nuclear Medicine Market, by Application, 2023-2030 (USD Million)
Table 184 France: Nuclear Medicine Market for Diagnostic Applications, by Type, 2023-2030 (USD Million)
Table 185 France: Nuclear Medicine Market for Spect Applications, by Type, 2023-2030 (USD Million)
Table 186 France: Nuclear Medicine Market for Pet Applications, by Type, 2023-2030 (USD Million)
Table 187 France: Nuclear Medicine Market for Therapeutic Applications, by Type, 2023-2030 (USD Million)
Table 188 France: Nuclear Medicine Market, by End-user, 2023-2030 (USD Million)
Table 189 UK: Nuclear Medicine Market, by Type, 2023-2030 (USD Million)
Table 190 UK: Diagnostic Nuclear Medicine Market, by Type, 2023-2030 (USD Million)
Table 191 UK: Nuclear Medicine Market for Spect Radiopharmaceuticals, by Type, 2023-2030 (USD Million)
Table 192 UK: Nuclear Medicine Market for Pet Radiopharmaceuticals, by Type, 2023-2030 (USD Million)
Table 193 UK: Therapeutic Nuclear Medicine Market, by Type, 2023-2030 (USD Million)
Table 194 UK: Nuclear Medicine Market for Beta Emitters, by Type, 2023-2030 (USD Million)
Table 195 UK: Nuclear Medicine Market for Brachytherapy Isotopes, by Type, 2023-2030 (USD Million)
Table 196 UK: Nuclear Medicine Market, by Application, 2023-2030 (USD Million)
Table 197 UK: Nuclear Medicine Market for Diagnostic Applications, by Type, 2023-2030 (USD Million)
Table 198 UK: Nuclear Medicine Market for Spect Applications, by Type, 2023-2030 (USD Million)
Table 199 UK: Nuclear Medicine Market for Pet Applications, by Type, 2023-2030 (USD Million)
Table 200 UK: Nuclear Medicine Market for Therapeutic Applications, by Type, 2023-2030 (USD Million)
Table 201 UK: Nuclear Medicine Market, by End-user, 2023-2030 (USD Million)
Table 202 Italy: Cancer Incidence, by Cancer Type, 2020 vs. 2040
Table 203 Italy: Nuclear Medicine Market, by Type, 2023-2030 (USD Million)
Table 204 Italy: Diagnostic Nuclear Medicine Market, by Type, 2023-2030 (USD Million)
Table 205 Italy: Nuclear Medicine Market for Spect Radiopharmaceuticals, by Type, 2023-2030 (USD Million)
Table 206 Italy: Nuclear Medicine Market for Pet Radiopharmaceuticals, by Type, 2023-2030 (USD Million)
Table 207 Italy: Therapeutic Nuclear Medicine Market, by Type, 2023-2030 (USD Million)
Table 208 Italy: Nuclear Medicine Market for Beta Emitters, by Type, 2023-2030 (USD Million)
Table 209 Italy: Nuclear Medicine Market for Brachytherapy Isotopes, by Type, 2023-2030 (USD Million)
Table 210 Italy: Nuclear Medicine Market, by Application, 2023-2030 (USD Million)
Table 211 Italy: Nuclear Medicine Market for Diagnostic Applications, by Type, 2023-2030 (USD Million)
Table 212 Italy: Nuclear Medicine Market for Spect Applications, by Type, 2023-2030 (USD Million)
Table 213 Italy: Nuclear Medicine Market for Pet Applications, by Type, 2023-2030 (USD Million)
Table 214 Italy: Nuclear Medicine Market for Therapeutic Applications, by Type, 2023-2030 (USD Million)
Table 215 Italy: Nuclear Medicine Market, by End-user, 2023-2030 (USD Million)
Table 216 Spain: Nuclear Medicine Market, by Type, 2023-2030 (USD Million)
Table 217 Spain: Diagnostic Nuclear Medicine Market, by Type, 2023-2030 (USD Million)
Table 218 Spain: Nuclear Medicine Market for Spect Radiopharmaceuticals, by Type, 2023-2030 (USD Million)
Table 219 Spain: Nuclear Medicine Market for Pet Radiopharmaceuticals, by Type, 2023-2030 (USD Million)
Table 220 Spain: Therapeutic Nuclear Medicine Market, by Type, 2023-2030 (USD Million)
Table 221 Spain: Nuclear Medicine Market for Beta Emitters, by Type, 2023-2030 (USD Million)
Table 222 Spain: Nuclear Medicine Market for Brachytherapy Isotopes, by Type, 2023-2030 (USD Million)
Table 223 Spain: Nuclear Medicine Market, by Application, 2023-2030 (USD Million)
Table 224 Spain: Nuclear Medicine Market for Diagnostic Applications, by Type, 2023-2030 (USD Million)
Table 225 Spain: Nuclear Medicine Market for Spect Applications, by Type, 2023-2030 (USD Million)
Table 226 Spain: Nuclear Medicine Market for Pet Applications, by Type, 2023-2030 (USD Million)
Table 227 Spain: Nuclear Medicine Market for Therapeutic Applications, by Type, 2023-2030 (USD Million)
Table 228 Spain: Nuclear Medicine Market, by End-user, 2023-2030 (USD Million)
Table 229 Rest of Europe: Nuclear Medicine Market, by Type, 2023-2030 (USD Million)
Table 230 Rest of Europe: Diagnostic Nuclear Medicine Market, by Type, 2023-2030 (USD Million)
Table 231 Rest of Europe: Nuclear Medicine Market for Spect Radiopharmaceuticals, by Type, 2023-2030 (USD Million)
Table 232 Rest of Europe: Nuclear Medicine Market for Pet Radiopharmaceuticals, by Type, 2023-2030 (USD Million)
Table 233 Rest of Europe: Therapeutic Nuclear Medicine Market, by Type, 2023-2030 (USD Million)
Table 234 Rest of Europe: Nuclear Medicine Market for Beta Emitters, by Type, 2023-2030 (USD Million)
Table 235 Rest of Europe: Nuclear Medicine Market for Brachytherapy Isotopes, by Type, 2023-2030 (USD Million)
Table 236 Rest of Europe: Nuclear Medicine Market, by Application, 2023-2030 (USD Million)
Table 237 Rest of Europe: Nuclear Medicine Market for Diagnostic Applications, by Type, 2023-2030 (USD Million)
Table 238 Rest of Europe: Nuclear Medicine Market for Spect Applications, by Type, 2023-2030 (USD Million)
Table 239 Rest of Europe: Nuclear Medicine Market for Pet Applications, by Type, 2023-2030 (USD Million)
Table 240 Rest of Europe: Nuclear Medicine Market for Therapeutic Applications, by Type, 2023-2030 (USD Million)
Table 241 Rest of Europe: Nuclear Medicine Market, by End-user, 2023-2030 (USD Million)
Table 242 Asia-Pacific: Key Macroeconomic Indicators
Table 243 Asia-Pacific: Nuclear Medicine Market, by Country, 2023-2030 (USD Million)
Table 244 Asia-Pacific: Nuclear Medicine Market, by Type, 2023-2030 (USD Million)
Table 245 Asia-Pacific: Diagnostic Nuclear Medicine Market, by Type, 2023-2030 (USD Million)
Table 246 Asia-Pacific: Nuclear Medicine Market for Spect Radiopharmaceuticals, by Type, 2023-2030 (USD Million)
Table 247 Asia-Pacific: Nuclear Medicine Market for Pet Radiopharmaceuticals, by Type, 2023-2030 (USD Million)
Table 248 Asia-Pacific: Therapeutic Nuclear Medicine Market, by Type, 2023-2030 (USD Million)
Table 249 Asia-Pacific: Nuclear Medicine Market for Beta Emitters, by Type, 2023-2030 (USD Million)
Table 250 Asia-Pacific: Nuclear Medicine Market for Brachytherapy Isotopes, by Type, 2023-2030 (USD Million)
Table 251 Asia-Pacific: Nuclear Medicine Market, by Application, 2023-2030 (USD Million)
Table 252 Asia-Pacific: Nuclear Medicine Market for Diagnostic Applications, by Type, 2023-2030 (USD Million)
Table 253 Asia-Pacific: Nuclear Medicine Market for Spect Applications, by Type, 2023-2030 (USD Million)
Table 254 Asia-Pacific: Nuclear Medicine Market for Pet Applications, by Type, 2023-2030 (USD Million)
Table 255 Asia-Pacific: Nuclear Medicine Market for Therapeutic Applications, by Type, 2023-2030 (USD Million)
Table 256 Asia-Pacific: Nuclear Medicine Market, by End-user, 2023-2030 (USD Million)
Table 257 Japan: Nuclear Medicine Market, by Type, 2023-2030 (USD Million)
Table 258 Japan: Diagnostic Nuclear Medicine Market, by Type, 2023-2030 (USD Million)
Table 259 Japan: Nuclear Medicine Market for Spect Radiopharmaceuticals, by Type, 2023-2030 (USD Million)
Table 260 Japan: Nuclear Medicine Market for Pet Radiopharmaceuticals, by Type, 2023-2030 (USD Million)
Table 261 Japan: Therapeutic Nuclear Medicine Market, by Type, 2023-2030 (USD Million)
Table 262 Japan: Nuclear Medicine Market for Beta Emitters, by Type, 2023-2030 (USD Million)
Table 263 Japan: Nuclear Medicine Market for Brachytherapy Isotopes, by Type, 2023-2030 (USD Million)
Table 264 Japan: Nuclear Medicine Market, by Application, 2023-2030 (USD Million)
Table 265 Japan: Nuclear Medicine Market for Diagnostic Applications, by Type, 2023-2030 (USD Million)
Table 266 Japan: Nuclear Medicine Market for Spect Applications, by Type, 2023-2030 (USD Million)
Table 267 Japan: Nuclear Medicine Market for Pet Applications, by Type, 2023-2030 (USD Million)
Table 268 Japan: Nuclear Medicine Market for Therapeutic Applications, by Type, 2023-2030 (USD Million)
Table 269 Japan: Nuclear Medicine Market, by End-user, 2023-2030 (USD Million)
Table 270 China: Cancer Incidence, by Cancer Type, 2020 vs. 2040
Table 271 China: Nuclear Medicine Market, by Type, 2023-2030 (USD Million)
Table 272 China: Diagnostic Nuclear Medicine Market, by Type, 2023-2030 (USD Million)
Table 273 China: Nuclear Medicine Market for Spect Radiopharmaceuticals, by Type, 2023-2030 (USD Million)
Table 274 China: Nuclear Medicine Market for Pet Radiopharmaceuticals, by Type, 2023-2030 (USD Million)
Table 275 China: Therapeutic Nuclear Medicine Market, by Type, 2023-2030 (USD Million)
Table 276 China: Nuclear Medicine Market for Beta Emitters, by Type, 2023-2030 (USD Million)
Table 277 China: Nuclear Medicine Market for Brachytherapy Isotopes, by Type, 2023-2030 (USD Million)
Table 278 China: Nuclear Medicine Market, by Application, 2023-2030 (USD Million)
Table 279 China: Nuclear Medicine Market for Diagnostic Applications, by Type, 2023-2030 (USD Million)
Table 280 China: Nuclear Medicine Market for Spect Applications, by Type, 2023-2030 (USD Million)
Table 281 China: Nuclear Medicine Market for Pet Applications, by Type, 2023-2030 (USD Million)
Table 282 China: Nuclear Medicine Market for Therapeutic Applications, by Type, 2023-2030 (USD Million)
Table 283 China: Nuclear Medicine Market, by End-user, 2023-2030 (USD Million)
Table 284 India: Nuclear Medicine Market, by Type, 2023-2030 (USD Million)
Table 285 India: Diagnostic Nuclear Medicine Market, by Type, 2023-2030 (USD Million)
Table 286 India: Nuclear Medicine Market for Spect Radiopharmaceuticals, by Type, 2023-2030 (USD Million)
Table 287 India: Nuclear Medicine Market for Pet Radiopharmaceuticals, by Type, 2023-2030 (USD Million)
Table 288 India: Therapeutic Nuclear Medicine Market, by Type, 2023-2030 (USD Million)
Table 289 India: Nuclear Medicine Market for Beta Emitters, by Type, 2023-2030 (USD Million)
Table 290 India: Nuclear Medicine Market for Brachytherapy Isotopes, by Type, 2023-2030 (USD Million)
Table 291 India: Nuclear Medicine Market, by Application, 2023-2030 (USD Million)
Table 292 India: Nuclear Medicine Market for Diagnostic Applications, by Type, 2023-2030 (USD Million)
Table 293 India: Nuclear Medicine Market for Spect Applications, by Type, 2023-2030 (USD Million)
Table 294 India: Nuclear Medicine Market for Pet Applications, by Type, 2023-2030 (USD Million)
Table 295 India: Nuclear Medicine Market for Therapeutic Applications, by Type, 2023-2030 (USD Million)
Table 296 India: Nuclear Medicine Market, by End-user, 2023-2030 (USD Million)
Table 297 South Korea: Nuclear Medicine Market, by Type, 2023-2030 (USD Million)
Table 298 South Korea: Diagnostic Nuclear Medicine Market, by Type, 2023-2030 (USD Million)
Table 299 South Korea: Nuclear Medicine Market for Spect Radiopharmaceuticals, by Type, 2023-2030 (USD Million)
Table 300 South Korea: Nuclear Medicine Market for Pet Radiopharmaceuticals, by Type, 2023-2030 (USD Million)
Table 301 South Korea: Therapeutic Nuclear Medicine Market, by Type, 2023-2030 (USD Million)
Table 302 South Korea: Nuclear Medicine Market for Beta Emitters, by Type, 2023-2030 (USD Million)
Table 303 South Korea: Nuclear Medicine Market for Brachytherapy Isotopes, by Type, 2023-2030 (USD Million)
Table 304 South Korea: Nuclear Medicine Market, by Application, 2023-2030 (USD Million)
Table 305 South Korea: Nuclear Medicine Market for Diagnostic Applications, by Type, 2023-2030 (USD Million)
Table 306 South Korea: Nuclear Medicine Market for Spect Applications, by Type, 2023-2030 (USD Million)
Table 307 South Korea: Nuclear Medicine Market for Pet Applications, by Type, 2023-2030 (USD Million)
Table 308 South Korea: Nuclear Medicine Market for Therapeutic Applications, by Type, 2023-2030 (USD Million)
Table 309 South Korea: Nuclear Medicine Market, by End-user, 2023-2030 (USD Million)
Table 310 Australia: Nuclear Medicine Market, by Type, 2023-2030 (USD Million)
Table 311 Australia: Diagnostic Nuclear Medicine Market, by Type, 2023-2030 (USD Million)
Table 312 Australia: Nuclear Medicine Market for Spect Radiopharmaceuticals, by Type, 2023-2030 (USD Million)
Table 313 Australia: Nuclear Medicine Market for Pet Radiopharmaceuticals, by Type, 2023-2030 (USD Million)
Table 314 Australia: Therapeutic Nuclear Medicine Market, by Type, 2023-2030 (USD Million)
Table 315 Australia: Nuclear Medicine Market for Beta Emitters, by Type, 2023-2030 (USD Million)
Table 316 Australia: Nuclear Medicine Market for Brachytherapy Isotopes, by Type, 2023-2030 (USD Million)
Table 317 Australia: Nuclear Medicine Market, by Application, 2023-2030 (USD Million)
Table 318 Australia: Nuclear Medicine Market for Diagnostic Applications, by Type, 2023-2030 (USD Million)
Table 319 Australia: Nuclear Medicine Market for Spect Applications, by Type, 2023-2030 (USD Million)
Table 320 Australia: Nuclear Medicine Market for Pet Applications, by Type, 2023-2030 (USD Million)
Table 321 Australia: Nuclear Medicine Market for Therapeutic Applications, by Type, 2023-2030 (USD Million)
Table 322 Australia: Nuclear Medicine Market, by End-user, 2023-2030 (USD Million)
Table 323 Rest of Asia-Pacific: Nuclear Medicine Market, by Type, 2023-2030 (USD Million)
Table 324 Rest of Asia-Pacific: Diagnostic Nuclear Medicine Market, by Type, 2023-2030 (USD Million)
Table 325 Rest of Asia-Pacific: Nuclear Medicine Market for Spect Radiopharmaceuticals, by Type, 2023-2030 (USD Million)
Table 326 Rest of Asia-Pacific: Nuclear Medicine Market for Pet Radiopharmaceuticals, by Type, 2023-2030 (USD Million)
Table 327 Rest of Asia-Pacific: Therapeutic Nuclear Medicine Market, by Type, 2023-2030 (USD Million)
Table 328 Rest of Asia-Pacific: Nuclear Medicine Market for Beta Emitters, by Type, 2023-2030 (USD Million)
Table 329 Rest of Asia-Pacific: Nuclear Medicine Market for Brachytherapy Isotopes, by Type, 2023-2030 (USD Million)
Table 330 Rest of Asia-Pacific: Nuclear Medicine Market, by Application, 2023-2030 (USD Million)
Table 331 Rest of Asia-Pacific: Nuclear Medicine Market for Diagnostic Applications, by Type, 2023-2030 (USD Million)
Table 332 Rest of Asia-Pacific: Nuclear Medicine Market for Spect Applications, by Type, 2023-2030 (USD Million)
Table 333 Rest of Asia-Pacific: Nuclear Medicine Market for Pet Applications, by Type, 2023-2030 (USD Million)
Table 334 Rest of Asia-Pacific: Nuclear Medicine Market for Therapeutic Applications, by Type, 2023-2030 (USD Million)
Table 335 Rest of Asia-Pacific: Nuclear Medicine Market, by End-user, 2023-2030 (USD Million)
Table 336 Latin America: Key Macroeconomic Indicators
Table 337 Latin America: Nuclear Medicine Market, by Country, 2023-2030 (USD Million)
Table 338 Latin America: Nuclear Medicine Market, by Type, 2023-2030 (USD Million)
Table 339 Latin America: Diagnostic Nuclear Medicine Market, by Type, 2023-2030 (USD Million)
Table 340 Latin America: Nuclear Medicine Market for Spect Radiopharmaceuticals, by Type, 2023-2030 (USD Million)
Table 341 Latin America: Nuclear Medicine Market for Pet Radiopharmaceuticals, by Type, 2023-2030 (USD Million)
Table 342 Latin America: Therapeutic Nuclear Medicine Market, by Type, 2023-2030 (USD Million)
Table 343 Latin America: Nuclear Medicine Market for Beta Emitters, by Type, 2023-2030 (USD Million)
Table 344 Latin America: Nuclear Medicine Market for Brachytherapy Isotopes, by Type, 2023-2030 (USD Million)
Table 345 Latin America: Nuclear Medicine Market, by Application, 2023-2030 (USD Million)
Table 346 Latin America: Nuclear Medicine Market for Diagnostic Applications, by Type, 2023-2030 (USD Million)
Table 347 Latin America: Nuclear Medicine Market for Spect Applications, by Type, 2023-2030 (USD Million)
Table 348 Latin America: Nuclear Medicine Market for Pet Applications, by Type, 2023-2030 (USD Million)
Table 349 Latin America: Nuclear Medicine Market for Therapeutic Applications, by Type, 2023-2030 (USD Million)
Table 350 Latin America: Nuclear Medicine Market, by End-user, 2023-2030 (USD Million)
Table 351 Brazil: Nuclear Medicine Market, by Type, 2023-2030 (USD Million)
Table 352 Brazil: Diagnostic Nuclear Medicine Market, by Type, 2023-2030 (USD Million)
Table 353 Brazil: Nuclear Medicine Market for Spect Radiopharmaceuticals, by Type, 2023-2030 (USD Million)
Table 354 Brazil: Nuclear Medicine Market for Pet Radiopharmaceuticals, by Type, 2023-2030 (USD Million)
Table 355 Brazil: Therapeutic Nuclear Medicine Market, by Type, 2023-2030 (USD Million)
Table 356 Brazil: Nuclear Medicine Market for Beta Emitters, by Type, 2023-2030 (USD Million)
Table 357 Brazil: Nuclear Medicine Market for Brachytherapy Isotopes, by Type, 2023-2030 (USD Million)
Table 358 Brazil: Nuclear Medicine Market, by Application, 2023-2030 (USD Million)
Table 359 Brazil: Nuclear Medicine Market for Diagnostic Applications, by Type, 2023-2030 (USD Million)
Table 360 Brazil: Nuclear Medicine Market for Spect Applications, by Type, 2023-2030 (USD Million)
Table 361 Brazil: Nuclear Medicine Market for Pet Applications, by Type, 2023-2030 (USD Million)
Table 362 Brazil: Nuclear Medicine Market for Therapeutic Applications, by Type, 2023-2030 (USD Million)
Table 363 Brazil: Nuclear Medicine Market, by End-user, 2023-2030 (USD Million)
Table 364 Mexico: Nuclear Medicine Market, by Type, 2023-2030 (USD Million)
Table 365 Mexico: Diagnostic Nuclear Medicine Market, by Type, 2023-2030 (USD Million)
Table 366 Mexico: Nuclear Medicine Market for Spect Radiopharmaceuticals, by Type, 2023-2030 (USD Million)
Table 367 Mexico: Nuclear Medicine Market for Pet Radiopharmaceuticals, by Type, 2023-2030 (USD Million)
Table 368 Mexico: Therapeutic Nuclear Medicine Market, by Type, 2023-2030 (USD Million)
Table 369 Mexico: Nuclear Medicine Market for Beta Emitters, by Type, 2023-2030 (USD Million)
Table 370 Mexico: Nuclear Medicine Market for Brachytherapy Isotopes, by Type, 2023-2030 (USD Million)
Table 371 Mexico: Nuclear Medicine Market, by Application, 2023-2030 (USD Million)
Table 372 Mexico: Nuclear Medicine Market for Diagnostic Applications, by Type, 2023-2030 (USD Million)
Table 373 Mexico: Nuclear Medicine Market for Spect Applications, by Type, 2023-2030 (USD Million)
Table 374 Mexico: Nuclear Medicine Market for Pet Applications, by Type, 2023-2030 (USD Million)
Table 375 Mexico: Nuclear Medicine Market for Therapeutic Applications, by Type, 2023-2030 (USD Million)
Table 376 Mexico: Nuclear Medicine Market, by End-user, 2023-2030 (USD Million)
Table 377 Rest of Latin America: Nuclear Medicine Market, by Type, 2023-2030 (USD Million)
Table 378 Rest of Latin America: Diagnostic Nuclear Medicine Market, by Type, 2023-2030 (USD Million)
Table 379 Rest of Latin America: Nuclear Medicine Market for Spect Radiopharmaceuticals, by Type, 2023-2030 (USD Million)
Table 380 Rest of Latin America: Nuclear Medicine Market for Pet Radiopharmaceuticals, by Type, 2023-2030 (USD Million)
Table 381 Rest of Latin America: Therapeutic Nuclear Medicine Market, by Type, 2023-2030 (USD Million)
Table 382 Rest of Latin America: Nuclear Medicine Market for Beta Emitters, by Type, 2023-2030 (USD Million)
Table 383 Rest of Latin America: Nuclear Medicine Market for Brachytherapy Isotopes, by Type, 2023-2030 (USD Million)
Table 384 Rest of Latin America: Nuclear Medicine Market, by Application, 2023-2030 (USD Million)
Table 385 Rest of Latin America: Nuclear Medicine Market for Diagnostic Applications, by Type, 2023-2030 (USD Million)
Table 386 Rest of Latin America: Nuclear Medicine Market for Spect Applications, by Type, 2023-2030 (USD Million)
Table 387 Rest of Latin America: Nuclear Medicine Market for Pet Applications, by Type, 2023-2030 (USD Million)
Table 388 Rest of Latin America: Nuclear Medicine Market for Therapeutic Applications, by Type, 2023-2030 (USD Million)
Table 389 Rest of Latin America: Nuclear Medicine Market, by End-user, 2023-2030 (USD Million)
Table 390 Middle East & Africa: Key Macroeconomic Indicators
Table 391 Middle East & Africa: Nuclear Medicine Market, by Region, 2023-2030 (USD Million)
Table 392 Middle East & Africa: Nuclear Medicine Market, by Type, 2023-2030 (USD Million)
Table 393 Middle East & Africa: Diagnostic Nuclear Medicine Market, by Type, 2023-2030 (USD Million)
Table 394 Middle East & Africa: Nuclear Medicine Market for Spect Radiopharmaceuticals, by Type, 2023-2030 (USD Million)
Table 395 Middle East & Africa: Nuclear Medicine Market for Pet Radiopharmaceuticals, by Type, 2023-2030 (USD Million)
Table 396 Middle East & Africa: Therapeutic Nuclear Medicine Market, by Type, 2023-2030 (USD Million)
Table 397 Middle East & Africa: Nuclear Medicine Market for Beta Emitters, by Type, 2023-2030 (USD Million)
Table 398 Middle East & Africa: Nuclear Medicine Market for Brachytherapy Isotopes, by Type, 2023-2030 (USD Million)
Table 399 Middle East & Africa: Nuclear Medicine Market, by Application, 2023-2030 (USD Million)
Table 400 Middle East & Africa: Nuclear Medicine Market for Diagnostic Applications, by Type, 2023-2030 (USD Million)
Table 401 Middle East & Africa: Nuclear Medicine Market for Spect Applications, by Type, 2023-2030 (USD Million)
Table 402 Middle East & Africa: Nuclear Medicine Market for Pet Applications, by Type, 2023-2030 (USD Million)
Table 403 Middle East & Africa: Nuclear Medicine Market for Therapeutic Applications, by Type, 2023-2030 (USD Million)
Table 404 Middle East & Africa: Nuclear Medicine Market, by End-user, 2023-2030 (USD Million)
Table 405 GCC Countries: Nuclear Medicine Market, by Type, 2023-2030 (USD Million)
Table 406 GCC Countries: Diagnostic Nuclear Medicine Market, by Type, 2023-2030 (USD Million)
Table 407 GCC Countries: Nuclear Medicine Market for Spect Radiopharmaceuticals, by Type, 2023-2030 (USD Million)
Table 408 GCC Countries: Nuclear Medicine Market for Pet Radiopharmaceuticals, by Type, 2023-2030 (USD Million)
Table 409 GCC Countries: Therapeutic Nuclear Medicine Market, by Type, 2023-2030 (USD Million)
Table 410 GCC Countries: Nuclear Medicine Market for Beta Emitters, by Type, 2023-2030 (USD Million)
Table 411 GCC Countries: Nuclear Medicine Market for Brachytherapy Isotopes, by Type, 2023-2030 (USD Million)
Table 412 GCC Countries: Nuclear Medicine Market, by Application, 2023-2030 (USD Million)
Table 413 GCC Countries: Nuclear Medicine Market for Diagnostic Applications, by Type, 2023-2030 (USD Million)
Table 414 GCC Countries: Nuclear Medicine Market for Spect Applications, by Type, 2023-2030 (USD Million)
Table 415 GCC Countries: Nuclear Medicine Market for Pet Applications, by Type, 2023-2030 (USD Million)
Table 416 GCC Countries: Nuclear Medicine Market for Therapeutic Applications, by Type, 2023-2030 (USD Million)
Table 417 GCC Countries: Nuclear Medicine Market, by End-user, 2023-2030 (USD Million)
Table 418 Rest of Middle East & Africa: Nuclear Medicine Market, by Type, 2023-2030 (USD Million)
Table 419 Rest of Middle East & Africa: Diagnostic Nuclear Medicine Market, by Type, 2023-2030 (USD Million)
Table 420 Rest of Middle East & Africa: Nuclear Medicine Market for Spect Radiopharmaceuticals, by Type, 2023-2030 (USD Million)
Table 421 Rest of Middle East & Africa: Nuclear Medicine Market for Pet Radiopharmaceuticals, by Type, 2023-2030 (USD Million)
Table 422 Rest of Middle East & Africa: Therapeutic Nuclear Medicine Market, by Type, 2023-2030 (USD Million)
Table 423 Rest of Middle East & Africa: Nuclear Medicine Market for Beta Emitters, by Type, 2023-2030 (USD Million)
Table 424 Rest of Middle East & Africa: Nuclear Medicine Market for Brachytherapy Isotopes, by Type, 2023-2030 (USD Million)
Table 425 Rest of Middle East & Africa: Nuclear Medicine Market, by Application, 2023-2030 (USD Million)
Table 426 Rest of Middle East & Africa: Nuclear Medicine Market for Diagnostic Applications, by Type, 2023-2030 (USD Million)
Table 427 Rest of Middle East & Africa: Nuclear Medicine Market for Spect Applications, by Type, 2023-2030 (USD Million)
Table 428 Rest of Middle East & Africa: Nuclear Medicine Market for Pet Applications, by Type, 2023-2030 (USD Million)
Table 429 Rest of Middle East & Africa: Nuclear Medicine Market for Therapeutic Applications, by Type, 2023-2030 (USD Million)
Table 430 Rest of Middle East & Africa: Nuclear Medicine Market, by End-user, 2023-2030 (USD Million)
Table 431 Overview of Strategies Adopted by Key Players in Nuclear Medicine, January 2022-December 2025
Table 432 Nuclear Medicine Market: Degree of Competition
Table 433 Nuclear Medicine Market: Region Footprint
Table 434 Nuclear Medicine Market: Type Footprint
Table 435 Nuclear Medicine Market: Application Footprint
Table 436 Nuclear Medicine Market: Detailed List of Key Startup/SME Players
Table 437 Nuclear Medicine Market: Competitive Benchmarking of Key Emerging Players/Startups, by Region
Table 438 Nuclear Medicine Market: Competitive Benchmarking of Key Emerging Players/Startups, by Type
Table 439 Nuclear Medicine Market: Competitive Benchmarking of Key Emerging Players/Startups, by Application
Table 440 Nuclear Medicine Market: Product Approvals, January 2022- December 2025
Table 441 Nuclear Medicine Market: Deals, January 2022-December 2025
Table 442 Nuclear Medicine Market: Expansions, January 2022-December 2025
Table 443 Nuclear Medicine Market: Other Developments, January 2022-December 2025
Table 444 Novartis AG: Company Overview
Table 445 Novartis AG: Products Offered
Table 446 Novartis AG: Product Approvals, January 2022-December 2025
Table 447 Novartis AG: Deals, January 2022-December 2025
Table 448 Novartis AG: Expansions, January 2022-December 2025
Table 449 Lantheus Holdings, Inc.: Company Overview
Table 450 Lantheus Holdings, Inc.: Products Offered
Table 451 Lantheus Holdings, Inc.: Deals, January 2022-December 2025
Table 452 GE Healthcare: Company Overview
Table 453 GE Healthcare: Products Offered
Table 454 GE Healthcare: Product Approvals, January 2022-December 2025
Table 455 GE Healthcare: Deals, January 2022-December 2025
Table 456 GE Healthcare: Expansions, January 2022-December 2025
Table 457 GE Healthcare: Other Developments, January 2022-December 2025
Table 458 Curium: Company Overview
Table 459 Curium: Products Offered
Table 460 Curium: Product Approvals & Enhancements, January 2022-December 2025
Table 461 Curium: Deals, January 2022-December 2025
Table 462 Curium: Expansions, January 2022-December 2025
Table 463 Curium: Other Developments, January 2022-December 2025
Table 464 Telix Pharmaceuticals Limited: Company Overview
Table 465 Telix Pharmaceuticals Limited: Products Offered
Table 466 Telix Pharmaceuticals Limited: Product Approvals, January 2022-December 2025
Table 467 Telix Pharmaceuticals Limited: Deals, January 2022-December 2025
Table 468 Telix Pharmaceuticals Limited: Other Developments, January 2022-December 2025
Table 469 Siemens Healthineers: Company Overview
Table 470 Siemens Healthineers: Products Offered
Table 471 Siemens Healthineers: Deals, January 2022-December 2025
Table 472 Siemens Healthineers: Other Developments, January 2022-December 2025
Table 473 China Isotope & Radiation Corporation: Company Overview
Table 474 China Isotope & Radiation Corporation: Products Offered
Table 475 China Isotope & Radiation Corporation: Other Developments, January 2022-December 2025
Table 476 Bayer AG: Company Overview
Table 477 Bayer AG: Products Offered
Table 478 Bayer AG: Deals, January 2022-December 2025
Table 479 Bracco Imaging S.P.A.: Company Overview
Table 480 Bracco Imaging S.P.A.: Products Offered
Table 481 Bracco Imaging S.P.A.: Product Approvals, January 2022-December 2025
Table 482 Bracco Imaging S.P.A.: Deals, January 2022-December 2025
Table 483 Bracco Imaging S.P.A.: Other Develeopments, January 2022-December 2025
Table 484 Cardinal Health: Company Overview
Table 485 Cardinal Health: Products Offered
Table 486 Cardinal Health: Deals, January 2022-December 2025
Table 487 Jubilant Pharmova Limited: Company Overview
Table 488 Jubilant Pharmova Limited: Products Offered
Table 489 Jubilant Pharmova Limited: Product Approvals, January 2022-December 2025
Table 490 Jubilant Pharmova Limited: Deals, January 2022-December 2025
Table 491 Jubilant Pharmova Limited: Other Developments, January 2022-December 2025
Table 492 Eli Lilly and Company: Company Overview
Table 493 Eli Lilly and Company: Products Offered
Table 494 Eli Lilly and Company: Deals, January 2022-December 2025
Table 495 Eli Lilly and Company: Other Developments, January 2022-December 2025
Table 496 Bwxt Medical Ltd.: Company Overview
Table 497 Bwxt Medical Ltd.: Products Offered
Table 498 Bwxt Medical Ltd.: Product Approvals, January 2022-December 2025
Table 499 Ntp Radioisotopes Soc Ltd.: Company Overview
Table 500 Ntp Radioisotopes Soc Ltd.: Products Offered
Table 501 Ntp Radioisotopes Soc Ltd.: Deals, January 2022-December 2025
Table 502 Eckert & Ziegler: Company Overview
Table 503 Eckert & Ziegler: Products Offered
Table 504 Eckert & Ziegler: Product Approvals, January 2022-December 2025
Table 505 Eckert & Ziegler: Deals, January 2022-December 2025
Table 506 Eckert & Ziegler: Expansions, January 2022-December 2025
Table 507 Joint Stock Company Isotope (Isotope Jsc): Company Overview
Table 508 Isotope Jsc: Products Offered
Table 509 Isotope Jsc: Deals, January 2022-December 2025
Table 510 Isotope Jsc: Other Developments, January 2022-December 2025
Table 511 Pdradiopharma Inc.: Company Overview
Table 512 Pdradiopharma Inc.: Products Offered
Table 513 Pdradiopharma Inc.: Product Launches & Approvals, January 2022-December 2025
Table 514 Pdradiopharma Inc.: Deals, January 2022-December 2025
Table 515 Pdradiopharma Inc.: Expansions, January 2022-December 2025
Table 516 Itm Isotope Technologies Munich SE: Company Overview
Table 517 Itm Isotope Technologies Munich SE: Products Offered
Table 518 Itm Isotope Technologies Munich SE: Product Approvals, January 2022-December 2025
Table 519 Itm Isotope Technologies Munich SE: Deals, January 2022-December 2025
Table 520 Itm Isotope Technologies Munich SE: Expansions, January 2022-December 2025
Table 521 Itm Isotope Technologies Munich SE: Other Developments, January 2022-December 2025
Table 522 Narodowe Centrum Badan Jadrowych Osrodek Radioizotopów - Polatom: Company Overview
Table 523 Narodowe Centrum Badan Jadrowych Osrodek Radioizotopów - Polatom: Products Offered
Table 524 Narodowe Centrum Badan Jadrowych Osrodek Radioizotopów - Polatom: Deals, January 2022-December 2025
Table 525 Ansto: Company Overview
Table 526 Ansto: Products Offered
Table 527 Ansto: Deals, January 2022-December 2025
Table 528 Ansto: Other Developments, January 2022-December 2025
Table 529 Risk Assessment: Nuclear Medicine Market
List of Figures
Figure 1 Nuclear Medicine Market Segmentation & Regional Scope
Figure 2 Market Scenario
Figure 3 Global Nuclear Medicine Market, 2023-2030
Figure 4 Major Strategies Adopted by Key Players in Nuclear Medicine Market, 2022-2025
Figure 5 Disruptions Influencing Growth of Nuclear Medicine Market
Figure 6 High-Growth Segments in Nuclear Medicine Market, 2025-2030
Figure 7 Asia-Pacific to Register Highest CAGR in Nuclear Medicine Market, in Terms of Value, During Forecast Period
Figure 8 Rapid Expansion of Radioligand and Targeted Radionuclide Therapy to Drive Market Growth
Figure 9 Diagnostic Nuclear Medicine Market in North America Accounted for Largest Share in 2024
Figure 10 India to Register Highest Growth Rate During Forecast Period
Figure 11 Growth Rates of Emerging Economies to be Higher Than Those of Developed Economies During Forecast Period
Figure 12 Nuclear Medicine Market: Drivers, Restraints, Opportunities, and Challenges
Figure 13 Estimated Number of New Cases in Emerging Economies, 2022-2050
Figure 14 Nuclear Medicine Market: Porter's Five Forces Analysis
Figure 15 Global GDP Growth, 2020-2030
Figure 16 Nuclear Medicine Market: Value Chain Analysis (2024)
Figure 17 Nuclear Medicine Market: Ecosystem Analysis
Figure 18 Trends/Disruptions Impacting Customers’ Businesses
Figure 20 Patent Application Trends in Nuclear Medicine Market, 2015-2026
Figure 21 Jurisdiction & Top Applicant Analysis for Nuclear Medicine Market
Figure 22 Top Applicants & Owners (Companies/Institutions) for Nuclear Medicine Market (January 2015-February 2026)
Figure 23 Market Potential of AI/Gen AI on Nuclear Medicine Across End-users
Figure 24 Impact of AI/Gen AI on Interconnected & Adjacent Ecosystems
Figure 25 Influence of Stakeholders on Buying Process for End-users
Figure 26 Key Buying Criteria for Top Three End-users
Figure 27 North America: Nuclear Medicine Market Snapshot
Figure 28 Asia-Pacific: Nuclear Medicine Market Snapshot (2024)
Figure 29 Revenue Analysis of Key Players in Nuclear Medicine Market, 2020-2024
Figure 30 Market Share Analysis of Key Players in Nuclear Medicine Market, 2024
Figure 31 Nuclear Medicine Market: Brand/Product Comparative Analysis
Figure 32 EV/EBITDA of Key Vendors
Figure 33 Year-To-Date (YTD) Price Total Return and 5-Year Stock Beta of Key Vendors
Figure 34 Nuclear Medicine Market: Company Evaluation Matrix (Key Players), 2024
Figure 35 Nuclear Medicine Market: Company Footprint
Figure 36 Nuclear Medicine Market: Company Evaluation Matrix (Startups/SMEs), 2024
Figure 37 Novartis AG: Company Snapshot (2024)
Figure 38 Lantheus Holdings, Inc.: Company Snapshot (2024)
Figure 39 GE Healthcare: Company Snapshot (2024)
Figure 40 Telix Pharmaceuticals Limited: Company Snapshot (2024)
Figure 41 Siemens Healthineers: Company Snapshot (2024)
Figure 42 China Isotope & Radiation Corporation: Company Snapshot (2024)
Figure 43 Bayer AG: Company Snapshot (2024)
Figure 44 Cardinal Health: Company Snapshot (2024)
Figure 45 Jubilant Pharmova Limited: Company Snapshot (2024)
Figure 46 Eli Lilly and Company: Company Snapshot (2024)
Figure 47 Eckert & Ziegler: Company Snapshot (2024)
Figure 48 Ansto: Company Snapshot (2024)
Figure 49 Research Methodology: Nuclear Medicine Market
Figure 50 Research Design
Figure 51 Breakdown of Primary Interviews: by Company Type, Designation, and Region
Figure 52 Research Methodology: Hypothesis Building
Figure 53 Supply-Side Market Estimation: Revenue Share Analysis
Figure 54 Nuclear Medicine Market: Revenue Share Analysis Illustration
Figure 55 Nuclear Medicine Market: Revenue Analysis of Top Four Companies (2024)
Figure 56 Nuclear Medicine Market Size Estimation: Bottom-Up Approach
Figure 57 Nuclear Medicine Market Size Estimation: Top-Down Approach
Figure 58 CAGR Projections from Analysis of Market Drivers, Restraints, Opportunities, and Challenges in Nuclear Medicine Industry
Figure 59 CAGR Projections: Nuclear Medicine Market, 2025-2030
Figure 60 Data Triangulation Methodology
Figure 2 Market Scenario
Figure 3 Global Nuclear Medicine Market, 2023-2030
Figure 4 Major Strategies Adopted by Key Players in Nuclear Medicine Market, 2022-2025
Figure 5 Disruptions Influencing Growth of Nuclear Medicine Market
Figure 6 High-Growth Segments in Nuclear Medicine Market, 2025-2030
Figure 7 Asia-Pacific to Register Highest CAGR in Nuclear Medicine Market, in Terms of Value, During Forecast Period
Figure 8 Rapid Expansion of Radioligand and Targeted Radionuclide Therapy to Drive Market Growth
Figure 9 Diagnostic Nuclear Medicine Market in North America Accounted for Largest Share in 2024
Figure 10 India to Register Highest Growth Rate During Forecast Period
Figure 11 Growth Rates of Emerging Economies to be Higher Than Those of Developed Economies During Forecast Period
Figure 12 Nuclear Medicine Market: Drivers, Restraints, Opportunities, and Challenges
Figure 13 Estimated Number of New Cases in Emerging Economies, 2022-2050
Figure 14 Nuclear Medicine Market: Porter's Five Forces Analysis
Figure 15 Global GDP Growth, 2020-2030
Figure 16 Nuclear Medicine Market: Value Chain Analysis (2024)
Figure 17 Nuclear Medicine Market: Ecosystem Analysis
Figure 18 Trends/Disruptions Impacting Customers’ Businesses
Figure 20 Patent Application Trends in Nuclear Medicine Market, 2015-2026
Figure 21 Jurisdiction & Top Applicant Analysis for Nuclear Medicine Market
Figure 22 Top Applicants & Owners (Companies/Institutions) for Nuclear Medicine Market (January 2015-February 2026)
Figure 23 Market Potential of AI/Gen AI on Nuclear Medicine Across End-users
Figure 24 Impact of AI/Gen AI on Interconnected & Adjacent Ecosystems
Figure 25 Influence of Stakeholders on Buying Process for End-users
Figure 26 Key Buying Criteria for Top Three End-users
Figure 27 North America: Nuclear Medicine Market Snapshot
Figure 28 Asia-Pacific: Nuclear Medicine Market Snapshot (2024)
Figure 29 Revenue Analysis of Key Players in Nuclear Medicine Market, 2020-2024
Figure 30 Market Share Analysis of Key Players in Nuclear Medicine Market, 2024
Figure 31 Nuclear Medicine Market: Brand/Product Comparative Analysis
Figure 32 EV/EBITDA of Key Vendors
Figure 33 Year-To-Date (YTD) Price Total Return and 5-Year Stock Beta of Key Vendors
Figure 34 Nuclear Medicine Market: Company Evaluation Matrix (Key Players), 2024
Figure 35 Nuclear Medicine Market: Company Footprint
Figure 36 Nuclear Medicine Market: Company Evaluation Matrix (Startups/SMEs), 2024
Figure 37 Novartis AG: Company Snapshot (2024)
Figure 38 Lantheus Holdings, Inc.: Company Snapshot (2024)
Figure 39 GE Healthcare: Company Snapshot (2024)
Figure 40 Telix Pharmaceuticals Limited: Company Snapshot (2024)
Figure 41 Siemens Healthineers: Company Snapshot (2024)
Figure 42 China Isotope & Radiation Corporation: Company Snapshot (2024)
Figure 43 Bayer AG: Company Snapshot (2024)
Figure 44 Cardinal Health: Company Snapshot (2024)
Figure 45 Jubilant Pharmova Limited: Company Snapshot (2024)
Figure 46 Eli Lilly and Company: Company Snapshot (2024)
Figure 47 Eckert & Ziegler: Company Snapshot (2024)
Figure 48 Ansto: Company Snapshot (2024)
Figure 49 Research Methodology: Nuclear Medicine Market
Figure 50 Research Design
Figure 51 Breakdown of Primary Interviews: by Company Type, Designation, and Region
Figure 52 Research Methodology: Hypothesis Building
Figure 53 Supply-Side Market Estimation: Revenue Share Analysis
Figure 54 Nuclear Medicine Market: Revenue Share Analysis Illustration
Figure 55 Nuclear Medicine Market: Revenue Analysis of Top Four Companies (2024)
Figure 56 Nuclear Medicine Market Size Estimation: Bottom-Up Approach
Figure 57 Nuclear Medicine Market Size Estimation: Top-Down Approach
Figure 58 CAGR Projections from Analysis of Market Drivers, Restraints, Opportunities, and Challenges in Nuclear Medicine Industry
Figure 59 CAGR Projections: Nuclear Medicine Market, 2025-2030
Figure 60 Data Triangulation Methodology
Companies Mentioned
- Novartis AG
- Lantheus Holdings, Inc.
- GE Healthcare
- Curium
- Telix Pharmaceuticals Limited
- Siemens Healthineers
- China Isotope & Radiation Corporation
- Bayer AG
- Bracco Imaging S.P.A.
- Cardinal Health
- Jubilant Pharmova Limited
- Eli Lilly and Company
- Bwxt Medical Ltd.
- Ntp Radioisotopes Soc Ltd. (A Subsidiary of South African Nuclear Energy Corporation)
- Eckert & Ziegler
- Isotope Jsc
- Pdradiopharma Inc.
- Itm Isotope Technologies Munich SE
- Narodowe Centrum Badań Jądrowych Ośrodek Radioizotopów - Polatom
- Ansto
- Shine Technologies, LLC
- Isotopia Molecular Imaging Ltd.
- Institute of Isotopes
- Global Medical Solutions
- Isotex Diagnostics
Table Information
| Report Attribute | Details |
|---|---|
| No. of Pages | 536 |
| Published | January 2026 |
| Forecast Period | 2025 - 2030 |
| Estimated Market Value ( USD | $ 10.41 Billion |
| Forecasted Market Value ( USD | $ 21.01 Billion |
| Compound Annual Growth Rate | 15.1% |
| Regions Covered | Global |
| No. of Companies Mentioned | 25 |
